High-throughput mass spectrometric determination of glutathione

The method of derivatizing and purifying glutathione using mass spectrometry addresses the need for high-throughput glutathione measurement, providing accurate clinical assays with enhanced sensitivity and specificity.

WO2026236061A1PCT designated stage Publication Date: 2026-11-12QUEST DIAGNOSTICS INVESTMENTS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026319
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-01
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for measuring glutathione (GSH) lack high-throughput capabilities and accuracy for clinical diagnosis and prognosis, particularly in diseases associated with GSH deficiency or dysregulation, necessitating a more efficient and reliable assay.

Method used

A method involving mass spectrometry that includes derivatizing glutathione with reducing and derivatizing reagents, followed by liquid chromatography purification and ionization, allowing for the detection of glutathione ions to determine its presence or amount in a sample, optionally with internal standards for enhanced accuracy.

Benefits of technology

Enables high-throughput, clinically viable, and commercially useful assays for glutathione measurement with improved analytical and clinical reportable ranges, achieving high signal-to-noise ratios and minimizing analytical interference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026319_12112026_PF_FP_ABST
    Figure US2026026319_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Methods, systems, kits, and computer programs for determining presence and / or an amount of glutathione by mass spectrometry are disclosed herein. An aspect of the disclosure is a method for determining presence or an amount of glutathione by mass spectrometry, including subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the test sample using liquid chromatography, subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry, determining an amount of the one or more ions by mass spectrometry, and using the amount of the one or more ions to determine the amount of glutathione in the test sample.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No. J5363-26802HIGH-THROUGHPUT MASS SPECTROMETRIC DETERMINATION OF GEUTATHIONEREEATED APPLICATIONS

[0001] This disclosure claims the benefit of priority of U.S. Provisional Application No. 63 / 802,193 filed May 8, 2025, the contents of which are herein incorporated in its entirety.FIELD

[0002] The present disclosure relates to systems, methods, kits, and computer programs for measurement of glutathione, in particular by mass spectrometry. Glutathione is endogenous to human subjects and thus, the respective measurement may be used for disease diagnosis and / or prognosis.BACKGROUND

[0003] The background of the present disclosure is provided simply as an aid in understanding the technology as described herein and is not admitted as describing or constituting prior art to the disclosure.

[0004] Glutathione (GSH) is a major antioxidant in cellular organisms and is essential in maintaining oxidative equilibrium under normal physiological conditions. Therefore, GSH has been indicated as an early marker of several disease states including aging, cancer, and cardiovascular disease. In addition, GSH deficiency or dysregulation may be linked to e.g., neurodegenerative disorder, acquired immunodeficiency syndrome, cystic fibrosis, and liver disease. See, e.g., D. M. Townsend, et al., Biomed Pharmacother . 2003, 57 (3 - 4): 145 - 155. GSH is a tripeptide of glycine, glutamate, and cysteine. The cysteine contains a thiol (-SH) group that can be reversibly oxidized and reduced to form the dimer, glutathione disulfide (GSSG). GSH also forms disulfide bridges with proteins as a result of oxidation or enzyme catalyzed reactions, giving rise to protein-bound glutathione (GSSP).

[0005] Methods for measuring GSH have been described (see, e.g., U.S. Patent Nos. 9,869,684 and 12,216,125; D. T. Harwood, et al., Journal of Chromatography B 2009 , 877: 3393-3399; T. R. Sutton, et al., Redox Biology 2018, 16:359-380; R. L. G. Norris, et al., Journal of Chromatography B 2012, 898: 136-140; I. Squellerio, et al., Journal of Pharmaceutical and Biomedical Analysis 2012, 71: 111-118. Considering the significant and rapid increase in aging population and patients with neurodegenerative disorder and / or other GSH-deficiency related diseases, there is an urgent need to develop a clinical viable and commercially useful assay with high-throughput capabilities to provide an accurate and efficient measurement of GSH, for clinical diagnosis and / or prognosis.SUMMARY

[0006] The present disclosure describes methods for high-throughput measurement of GSH by mass spectrometry, as well as systems, kits, and computer programs to perform the described methods. TheDocket No. J5363-26802methods, systems, kits, and computer programs as disclosed here can fulfill the significant need for GSH measurement, as well as GSH-associated disease diagnosis and / or prognosis. Various embodiments of the present disclose show exceeding advantages over existing technologies, which will be described in more details.

[0007] One aspect of the present disclosure is a method for determining presence or an amount of glutathione by mass spectrometry. The method may include subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the test sample using liquid chromatography, subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry, determining an amount of the one or more ions by mass spectrometry, and using the amount of the one or more ions to determine the amount of glutathione in the test sample.

[0008] Another aspect of the present disclosure is a method for determining presence or an amount of glutathione by mass spectrometry. The method may include subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, adding one or more internal standards into the test sample, purifying the derivatized glutathione and the one or more internal standards from the test sample using liquid chromatography, subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry, determining an amount of the one or more glutathione ions by mass spectrometry, and using the amount of the one or more glutathione ions to determine an amount of glutathione in the test sample.

[0009] Another aspect of the present disclosure is a method for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay. The method may include obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, where the patient sample may be suspected of containing glutathione, subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the patient sample using liquid chromatography, subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry, determining an amount of the one or more ions by mass spectrometry, using the amount of the one or more ions to determine the amount of glutathione in the patient sample, and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0010] Another aspect of the present disclosure is a kit for use in a method of determining the presence or an amount of glutathione by mass spectrometry. The kit may comprise one or moreDocket No. J5363-26802internal standards. The internal standards may be isotopically labeled analogues of glutathione. In some aspects, the isotopically labeled analogues are deuterated.

[0011] Another aspect of the present disclosure is a method for detecting glutathione deficiency and / or dysfunction in a subject using a mass spectrometric assay. The method may include obtaining a sample from a subject suspected of or having a glutathione deficiency and / or dysfunction, where the sample may be suspected of containing glutathione, contacting the subject sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the subject sample using liquid chromatography, subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry, determining an amount of the one or more ions by mass spectrometry, using the amount of the one or more ions to determine the amount of glutathione in the subject sample, and identifying the subject with glutathione deficiency and / or dysfunction when the amount of glutathione in the subject sample exceeds a reference interval.

[0012] In some aspects of the present disclosure is a method of preparing a high-level derivatized glutathione composition by preparing derivatized glutathione from a sample obtained from a subject having a glutathione deficiency and / or dysfunction. In some aspects, this disclosure relates to a method of preparing a high level of ionized derivatized glutathione, the method comprising the steps of preparing derivatized glutathione from a sample obtained from a subject having a glutathione deficiency and / or dysfunction followed by performing mass spectrometry on the derivatized glutathione. In some aspects, the method further comprises adding an isotopically labeled internal standard as described herein to the sample. The term “high-level derivatized glutathione composition” is when the level of derivatized glutathione in the sample higher than a pre-selected reference interval level.

[0013] Another aspect of the present disclosure is a method for identifying subjects with glutathione deficiency and / or dysfunction with a mass spectrometric assay. The method may include obtaining a sample from a subject suspected of glutathione deficiency and / or dysfunction, where the subject sample may be suspected of containing glutathione, contacting the sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, contacting the sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, adding one or more internal standards into the sample, purifying the derivatized glutathione and the one or more internal standards from the subject sample using liquid chromatography, subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry, determining an amount of the one or more glutathione ions by mass spectrometry, and using the amount of the one or more glutathione ions to determine an amount of glutathione in the sample, and diagnosing the subjectDocket No. J5363-26802with glutathione deficiency and / or dysfunction when the amount of glutathione in the sample exceeds a reference interval.

[0014] In some embodiments, the method may further include extracting glutathione from the test sample prior to the purification. In some embodiments, the extracting may include protein precipitation from the test sample.

[0015] In some embodiments, the test sample may be subjected to acidic conditions. In some embodiments, contacting the test sample with acidic conditions may include contacting the test sample with formic acid.

[0016] In some embodiments, the reducing reagent may be selected from tris(2-carboxyethyljphosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0017] In some embodiments, the derivatizing reagent may include maleimide. In some embodiments, the derivatizing reagent may be selected from N-methyhnaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, N-ethylmaleimide. In some embodiments, the derivatizing reagent may include N-ethylmaleimide.

[0018] In some embodiments, the liquid chromatography may include high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), or high-resolution liquid chromatography .

[0019] In some embodiments, the purification may comprise liquid-liquid extraction and / or solid phase extraction.

[0020] In some embodiments, the ionization may include electrospray ionization. In some embodiments, the ionization may include heated electrospray ionization (HESI).

[0021] In some embodiments, the ionization may include atmospheric pressure chemical ionization (APCI).

[0022] In some preferred embodiments, the ionization may be in positive ion mode. In some embodiments, the ionization may be in negative ion mode.

[0023] In some embodiments, the mass spectrometry may be performed in multiple reaction monitoring mode.

[0024] In some embodiments, the mass spectrometry may include tandem mass spectrometry.

[0025] In some embodiments, the methods provided herein may have an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0026] In some embodiments, the methods provided herein may have a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0027] In some embodiments, the one or more ions may include one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.Docket No. J5363-26802

[0028] In some embodiments, the one or more ions may include one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0029] In some embodiments, the method may further include adding one or more internal standards into the test sample.

[0030] In some embodiments, the kit may further include adding one or more internal standards.

[0031] In some embodiments, the one or more internal standards may be isotopically labeled. In some embodiments, the one or more internal standards are labeled with one or more deuterium (2H),13C, and / or15N atoms.

[0032] In some embodiments, the one or more internal standards may be selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0033] In some embodiments, the method may further include ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0034] In some embodiments, the test sample may include a biological sample. In some embodiments, the test sample may include a bodily fluid. In some embodiments, the test sample may include whole blood.

[0035] In some embodiments, one or more of the steps of the methods may be performed on-line (e.g., within an LC-MS / MS instrument).

[0036] In some embodiments, the reference interval for glutathione may be 373-838 pmol / L (micromoles per liter).

[0037] In some embodiments, exceeding the reference interval may comprise greater than an upper limit of the reference interval and / or smaller than a lower limit of the reference interval.

[0038] Another aspect of the present disclosure is a system for determining presence or an amount of glutathione in a test sample using mass spectrometry. The system may include a reaction station for derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, a purification station for purifying the derivatized glutathione from the test sample by liquid chromatography, and a mass spectrometry station for ionizing the derivatized glutathione to generate one or more ions, and determining an amount of the one or more ions, where the amount of the one or more ions is related to presence or an amount of glutathione in the test sample.

[0039] Another aspect of the present disclosure is a system for determining presence or an amount of glutathione in a test sample using mass spectrometry, the system comprising: a reaction station for derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, and for adding one or more internal standards into the test sample; a purification station for purifying the derivatized glutathione and the one or more internal standards from the test sample by liquid chromatography; and a mass spectrometry station for ionizing theDocket No. J5363-26802derivatized glutathione and the one or more internal standards to generate one or more of glutathione ions and internal standard ions, and for determining an amount of the one or more glutathione ions, wherein the amount of the one or more glutathione ions is related to presence or an amount of glutathione in the test sample.

[0040] In some embodiments, the system may be an on-line system (e.g., within an LC-MS / MS instrument).

[0041] Another aspect of the present disclosure is non-transitory computer readable storage medium storing instructions that, when executed by at least one processor, cause a computing system to perform actions including derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the test sample using liquid chromatography, ionizing the derivatized glutathione under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry, determining an amount of the one or more ions by mass spectrometry, and using the amount of the one or more ions to determine the amount of glutathione in the test sample.

[0042] Another aspect of the present disclosure is non-transitory computer readable storage medium storing instructions that, when executed by at least one processor, cause a computing system to perform actions including subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, adding one or more internal standards into the test sample, purifying the derivatized glutathione and the one or more internal standards from the test sample using liquid chromatography, subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry, determining an amount of the one or more glutathione ions by mass spectrometry, and using the amount of the one or more glutathione ions to determine an amount of glutathione in the test sample.

[0043] The technology described in the present disclosure may provide various advantages. For example, it may provide a clinical viable and commercially useful assay developed with a complete set of validation results. It may also allow the high-throughput quantification of GSH without utilizing additional instruments, labor or time. Moreover, methods and systems described in various embodiments may provide a greater analytical measurement range and clinical reportable range compared to current technologies for GSH quantification. Also, high signal-to-noise ratio may be achieved when the disclosed methods and system are applied to patient samples, including, but not limited to, blood, plasma, and other bodily fluid with minimum analytical interference.BRIEF DESCRIPTION OF THE DRAWINGS

[0044] The drawings are generally placed upon illustrating the principles of the technology disclosed without limiting the scope of the disclosure, and are not necessarily drawn to scale.Docket No. J5363-26802

[0045] FIG. 1 depicts an exemplary workflow for quantitative measurement of GSH in accordance with various embodiments of the present disclosure;

[0046] FIG. 2 depicts an exemplary system for quantitative measurement of GSH in accordance with various embodiments of the present disclosure;

[0047] FIG. 3A depicts an exemplary chromatogram of derivatized GSH with respective counts in accordance with various embodiments of the present disclosure;

[0048] FIG. 3B depicts an exemplary chromatogram of derivatized GSH with respective relative abundance in accordance with various embodiments of the present disclosure;

[0049] FIG. 4A depicts an exemplary chromatogram of internal standard with respective counts in accordance with various embodiments of the present disclosure;

[0050] FIG. 4B depicts an exemplary chromatogram of internal standard with respective relative abundance in accordance with various embodiments of the present disclosure;

[0051] FIG. 5 depicts an exemplary calibration curve for quantitative measurement of GSH in accordance with various embodiments of the present disclosure;

[0052] FIG. 6 depicts an exemplary analytical measurement range (AMR) for quantitative measurement of GSH in accordance with various embodiments of the present disclosure; and

[0053] FIG. 7 depicts carryover effect of quantitative measurement of GSH in accordance with various embodiments of the present disclosure.DETAILED DESCRIPTION

[0054] The technology in the present disclosure will be described in more details with reference to the accompanying description and drawings. The technology in the present disclosure can be embodied in many different forms and should not be limited to the embodiments set forth here. Thus, the technology disclosed is not intended to be limited to the implementations shown, but is to be accorded the widest scope consistent with the principles and features disclosed herein.

[0055] The present disclosure is to enable those skilled in the art to make and use the technology disclosed, and is provided in the context of particular applications and requirements. Although specific terms may be employed in the disclosure, they are used in a generic and descriptive manner, and not for purposes of limitation. Various modifications to the disclosed embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other implementations and applications without departing from the spirit and scope of the technology disclosed.DEFINmONS

[0056] The following definitions are set forth to facilitate explanation of the technology as described herein. Unless otherwise defined, the terms described herein have the same meaning as commonly understood by those skilled in the art to which the presently disclosure belongs.Docket No. J5363-26802

[0057] Notwithstanding that some of the numerical ranges and parameters setting forth the broad scope of the present disclosure are approximations, numerical values set forth in the embodiments are reported as precise as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Furthermore, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed therein. For example, a stated range of “1 to 10” should be considered to include any and all subranges between (and inclusive of) the minimum value of 1 and the maximum value of 10.

[0058] As used herein, unless otherwise stated, the singular forms “a,” “an,” and “the” may refer to “one or more”. For example, a reference to “a protein” may include a plurality of protein molecules.

[0059] As used herein, the term “about” may be in reference to quantitative measurements not including the measurement of the mass of an ion, referring to the indicated value plus or minus 10%. In quantification measurement of analyte(s) using mass spectrometry, for example, mass spectrometry instruments may vary slightly in determining the mass of a given analyte. The term “about” in the context of the mass of an ion or the mass / charge ratio of an ion may refer to ± 0.5 atomic mass unit.

[0060] As used herein, an “amount” of an analyte in a sample may refer generally to an absolute value reflecting the mass of the analyte detectable in volume of the sample. However, an amount may also contemplate a relative amount in comparison to another analyte amount. For example, an amount of an analyte in a sample can be an amount which is greater than a control or normal level of the analyte normally present in the sample.

[0061] As used herein, the term “analyte” or “analyte of interest” may refer to a substance of interest that can be detected and / or measured. For example, an analyte may refer to a chemical compound, an ion, or a molecule that can be analyzed qualitatively or quantitatively.

[0062] As used herein, the term “analytical column” may refer to a chromatography column having sufficient chromatographic plates to effect separation of components in a sample that elute from the column sufficient to allow determination of the presence or amount of an analyte. In some embodiments, an analytical column may contain particles of about 1.8 - 5 pm in diameter. In some embodiments, an analytical column with smaller sized particles (e.g., 1.8 - 3 pm) may be used for high-speed and / or high-resolution chromatography. In some embodiments, the particles may be made of silica and / or polymer. Analytical columns may be distinguished from “large particle columns” or “extraction columns”, which have the general purpose of separating or extracting retained material from non-retained materials in order to obtain a purified sample for further analysis. As used herein, the term “large particle columns” or “extraction columns” may refer to a chromatography column containing an average particle diameter greater than about 35 pm. For example, an extraction column may contain particles of about 60 pm in diameter. The particles may be made of silica and / or polymer. In some embodiments, an extraction column or cartridge may be used in solid-phaseDocket No. J5363-26802extraction (SPE), where a sample passes through a solid stationary phase (e.g., the extraction column or cartridge) to separate and / or concentrate the analyte of interest.

[0063] As used herein, the term “analytical interference” may refer to a substance or a condition, present in a sample or introduced during an analytical process, that alters an expected analytical signal or result for the analyte of interest. An analytical interference may lead to an incorrect qualification or quantification of the analyte of interest, and / or reduced sensitivity and precision when measuring the analyte of interest.

[0064] As used herein, the term “analytical measurement range (AMR)” may refer to a range of analyte concentrations that an instrument can measure. In some embodiments, AMR may be measured without pretreatment of the sample (e.g., concentration or dilution).

[0065] As used herein, the term “analytical sensitivity” or “sensitivity” may refer to the ability of a measurement procedure or an assay to detect the lowest concentration or the smallest amount of an analyte in a sample. In some embodiments, analytical sensitivity may be referred to as limit of detection (LOD).

[0066] As used herein, the term “analytical specificity” or “specificity” may refer to the ability of a measurement procedure or an assay to discriminate an analyte of interest from other substances present in a sample. Some aspects of analytical specificity may comprise cross reactivity and interference. In some embodiments, analytical specificity may be expressed as a percentage of cross reactivity and / or response to interferences in the absence of the analyte of interest.

[0067] As used herein, the term “atmospheric pressure chemical ionization” or “APCI” may refer to an ionization method used in mass spectrometry that produces ions by ion-molecule reactions that occur within a plasma at atmospheric pressure. The plasma is maintained by an electric discharge between the spray capillary and a counter electrode. Then ions are typically extracted into the mass analyzer by use of a set of differentially pumped skimmer stages. A counterflow of dry and preheated N2 gas may be used to improve removal of solvent. Different from electrospray ionization (ESI) which will be explained further below, ions generated by APCI may be formed in the gas phase. This gas-phase ionization can be more effective than ESI when analyzing less-polar species.

[0068] As used herein, the term “atmospheric pressure photoionization” or “APPI” may refer to an ionization method using photoionization. A molecule (e.g., M) may be ionized to form a molecular ion (e.g. , M+) by absorption followed by electron ejection or through ionization of a dopant molecule that leads to chemical ionization of the molecule. Because the photon energy typically is just above the ionization potential, the molecular ion is less susceptible to dissociation. In many cases it may be possible to analyze samples without the need for chromatography, thus saving significant time and expense. In the presence of water vapor or protic solvents, the molecular ion can extract hydrogen (i.e., H) to form MH+. This tends to occur if M has a high proton affinity. This does not affectDocket No. J5363-26802quantitation accuracy because the sum of M+and MH+is constant. Compounds in protic solvents are usually observed as MH+, whereas nonpolar compounds usually form M+.

[0069] As used herein, the term “chemical ionization” or “CI” may refer to methods in which a reagent gas (e.g., ammonia, methane) is subjected to electron impact, and analyte ions are formed by the interaction of reagent gas ions and analyte molecules.

[0070] As used herein, the term “chromatography” may refer to a process in which a chemical mixture carried by a liquid or gas is separated into components as a result of differential distribution of the chemical entities as they flow around or over a stationary liquid or solid phase.Chromatography may include, but not limited to, gas chromatography, liquid chromatography, thin-layer chromatography, ion-exchange chromatography, and affinity chromatography.

[0071] As used herein, the term “derivatizing” or “derivatization” may refer to reacting two molecules to form a new molecule. Derivatizing reagents may include, but not limited not, isothiocyanate groups, dinitro-fluorophenyl groups, nitrophenoxy carbonyl groups, and / or phthalaldehyde groups.

[0072] As used herein, the term “desorption” may refer to the removal of an analyte from a surface and / or the entry of an analyte into a mobile phase. In chromatography, desorption may refer to the release of a previously adsorbed analyte from a stationary phase to a mobile phase.

[0073] As used herein, the term “electron ionization” or “El” may refer to methods in which an analyte of interest in a gaseous or vapor phase interacts with a flow of electrons. Impact of the electrons with the analyte produces analyte ions, which may then be subjected to mass spectrometry.

[0074] As used herein, the term “electrospray ionization” or “ESI” may refer to methods in which a solution is passed along a short length of capillary tube, to the end of which is applied a high positive or negative voltage. Solution reaching the end of the tube is vaporized (nebulized) into a jet or spray of very small droplets of solution in solvent vapor. This mist of droplets flows through an evaporation chamber, which is heated slightly to prevent condensation and to evaporate solvent. As the droplets get smaller the electrical surface charge density increases until such time that the natural repulsion between like charges causes ions as well as neutral molecules to be released. In some embodiments, ESI may produce multiple charged ions that can improve the sensitivity and resolution of mass spectrometry analysis.

[0075] As used herein, the term “fast atom bombardment” or “FAB” may refer to an ionization method in which a beam of high energy atoms (often Xe or Ar) impacts a non-volatile sample, desorbing and ionizing molecules contained in the sample. Test samples may be dissolved in a viscous liquid matrix such as glycerol, thioglycerol, m-nitrobenzyl alcohol, 18-crown-6 crown ether, 2-nitrophenyloctyl ether, sulfolane, diethanolamine, and triethanolamine. The choice of an appropriate matrix for a compound or sample is an empirical process.

[0076] As used herein, the term “field desorption” may refer to methods in which a non-volatile test sample is placed on an ionization surface, and an intense electric field is used to generate analyte ions.Docket No. J5363-26802

[0077] As used herein, the term “gas chromatography” or “GC” may refer to chromatography in which a sample is vaporized and injected into a stream of carrier gas (e.g., nitrogen, helium, hydrogen) moving through a column containing a stationary phase composed of liquid or solid material, and is separated into its component compounds according to the affinity of the compounds for the stationary phase. In some embodiments, a gas chromatography instrumentation may include a compressed gas source where gas provides a mobile phase, an injector that rapidly vaporizes a sample and introduces the sample into a separation column (e.g., packed column or a capillary column) where the separation process occurs based on the affinity of components in the sample with the stationary phase. Gas chromatography may be utilized to analyze thermally stable molecules in different applications, including determining purity of drugs and food products, and detecting trace contaminants.

[0078] As used herein, the term “high performance liquid chromatography” or “HPLC” may refer to liquid chromatography in which the degree of separation is increased by forcing the mobile phase under pressure through a stationary phase, typically a densely packed column. HPLC can be used in, for example, pharmaceutical, bioanalytical, clinical, and forensic laboratory settings.

[0079] As used herein, the term “high turbulence liquid chromatography” or “HTLC” may refer to a form of chromatography that utilizes turbulent flow of the material being assayed through the column packing as the basis for performing the separation. In some embodiments, HTLC may use columns with larger diameters or particle size, higher flow rates, and / or lower viscosity to increase the momentum of the fluid and thus generate turbulent flow. In contrast, when fluid flows slowly and smoothly, the flow is laminar. For example, fluid moving through an HPLC column at low flow rates is laminar. In laminar flow the motion of the particles of fluid is orderly with particles moving generally in straight lines. At faster velocities, the inertia of the water overcomes fluid frictional forces and turbulent flow results. Fluid not in contact with the irregular boundary “outruns” that which is slowed by friction or deflected by an uneven surface. When a fluid is flowing turbulently, it flows in eddies and whirls (or vortices), with more “drag” than when the flow is laminar. HTLC may provide faster sample separation and analysis, promote mixing of the sample with the mobile phase and therefore, achieve high throughput of sample analysis.

[0080] As used herein, the term “inductively coupled plasma” or “I CP” may refer to methods in which a sample interacts with a partially ionized gas at a sufficiently high temperature such that most elements are atomized and ionized.

[0081] As used herein, the term “internal standard” may refer to a known compound that is added into a sample for quantitative analysis, thereby correcting for variations in sample preparation and instrument performance, compensating for matrix effect, and improving the accuracy and precision of quantification of analyte of interest in the sample. An internal standard may be naturally absent or present at a very low concentration in the sample. In some embodiments, an internal standard may beDocket No. J5363-26802a structurally related compound of an analyte of interest. In other embodiments, an internal standard may be a stable labeled compound, for example, isotopically labeled.

[0082] As used herein, the term “intra-assay precision” may assess how closely results agree when the same sample is measured repeatedly in the same assay run. In some embodiments, intra-assay precision may be expressed as a coefficient of variation (CV).

[0083] As used herein, the term “inter-assay precision” may assess how closely results agree when a sample is measured in multiple assay runs. The multiple assay runs may be performed with different operating conditions, instruments, laboratories, analytical techniques, reagents, calibrators, operators, etc. In some embodiments, inter-assay precision may be expressed as CV.

[0084] As used herein, the term “ionization” or “ionizing” may refer to the process of generating an analyte ion having a net electrical charge equal to one or more electron units. Negative ions are those having a net negative charge of one or more electron units, while positive ions are those having a net positive charge of one or more electron units.

[0085] As used herein, an “isotopic label” may produce a mass shift in the labeled molecule relative to the unlabeled molecule when analyzed by mass spectrometric techniques. Examples of suitable labels include deuterium,13C,15N, and17O. Deuterium can be a useful label because it can potentially produce three mass unit shifts in a labeled methylation product relative to an unlabeled methylation product. An isotopic label may be incorporated at one or more positions in a molecule and one or more kinds of isotopic labels may be used on the same isotopically labeled molecule.

[0086] As used herein, the term “limit of detection” or “LOD” may refer to the lowest quantity or concentration of an analyte in a sample that can be reliably detected and discriminated from a blank sample that does not contain the analyte. In some embodiments, the LOD may be determined based on the slope of the calibration curve and the standard deviation of the response of the curve.

[0087] As used herein, the term “limit of quantification”, “limit of quantitation” or “LOQ” may refer to the point where measurements become quantitatively meaningful. The analyte response at this LOQ is identifiable, discrete and reproducible with acceptable precision and accuracy.

[0088] As used herein, the term “liquid chromatography” or “LC” means a process of selective retardation of one or more components of a fluid solution as the fluid uniformly percolates through a column of a finely divided substance, or through capillary passageways. The retardation results from the distribution of the components of the mixture between one or more stationary phases and the bulk fluid, (i.e., mobile phase), as this fluid moves relative to the stationary phase(s). Examples of liquid chromatography may include reverse phase liquid chromatography (RPLC), HPLC, HTLC, high resolution liquid chromatography, ultra-high performance liquid chromatography (UHPLC).

[0089] As used herein, the term “mass spectrometry” or “MS” may refer to an analytical technique to identify compounds by their mass. MS may refer to methods of filtering, detecting, and measuring ions based on their mass-to-charge ratio, or “m / z”. MS technology may include (1) ionizing theDocket No. J5363-26802compounds to form charged compounds; and (2) detecting the molecular weight of the charged compounds and calculating a mass-to-charge ratio. The compounds may be ionized and detected by any suitable means. A mass spectrometer may include an ionizer, a mass analyzer and an ion detector. In some embodiments, one or more molecules of interest may be ionized, and the ions may be subsequently introduced into a mass spectrographic instrument where, due to a combination of magnetic and electric fields, the ions may follow a path in space that is dependent upon mass (“m”) and charge (“z”).

[0090] As used herein, the term “matrix-assisted laser desorption ionization” or “MALDI” may refer to methods in which a non-volatile sample is exposed to laser irradiation, which desorbs and ionizes analytes in the sample by various ionization pathways, including photo-ionization, protonation, deprotonation, and cluster decay. For MALDI, a sample may be mixed with an energy-absorbing matrix, which facilitates desorption of analyte molecules.

[0091] As used herein, the term “high resolution / high accuracy mass spectrometry” may refer to mass spectrometry conducted with a mass analyzer capable of measuring m / z of a charged species with sufficient precision and accuracy to confirm a unique chemical ion. Confirmation of a unique chemical ion is possible for an ion when individual isotopic peaks from that ion are readily discernable. The particular resolving power and mass accuracy necessary to confirm a unique chemical ion varies with the mass and charge state of the ion. As used herein, the term “resolving power” or “FWHM” may refer to an observed m / z divided by the width of the mass peak at 50% maximum height (Full Width Half Maximum, “FWHM”). As used herein, the term “unique chemical ion” with respect to mass spectrometry may refer a single ion with a single atomic makeup. The single ion may be singly or multiply charged. High resolution / high accuracy mass spectrometry methods may be conducted on instruments capable of performing mass analysis with FWHM of greater than 10,000, 15,000, 20,000, 25,000, 50,000, 100,000, or more, high resolution / high accuracy mass spectrometry may be conducted on instruments capable of performing mass analysis with accuracy of less than 50 parts per million (ppm), 20 ppm, 15 ppm, 10 ppm, 5 ppm, 3 ppm, or less. Instruments capable of these performance characteristics may incorporate orbitrap mass analyzers, time-of-flight (“TOF”) mass analyzers, or Fourier-transform ion cyclotron resonance mass analyzers.

[0092] As used herein, the term “matrix effect” may refer to the influences of co-eluting components in a sample on the measurement of an analyte of interest. The matrix effect may lead to changes in signal intensity and impact the accuracy of measurement. In mass spectrometry settings, for example, co-eluting components may alter the ionization of target analyte as well as the chromatographic response of the analytes.

[0093] As used herein, “multiple reaction mode,” sometimes known as “selected reaction monitoring,” is a detection mode for a mass spectrometric instrument in which a precursor ion and one or more fragment ions are selectively detected.Docket No. J5363-26802

[0094] As used herein, the term “on-line” or “in-line”, for example as used in “on-line automated fashion” or “on-line extraction” may refer to a procedure performed without the need for operator intervention. In contrast, as used herein, the term “off-line” may refer to a procedure requiring manual intervention of an operator. Thus, if samples are subjected to precipitation, and the supernatants are then manually loaded into an autosampler, the precipitation and loading steps are off-line from the subsequent steps. In various embodiments of the present disclosure, one or more steps may be performed in an on-line automated fashion.

[0095] As used herein, the term “operating in negative ion mode” may refer to those mass spectrometry methods where negative ions are generated and detected. The term “operating in positive ion mode” as used herein, may refer to those mass spectrometry methods where positive ions are generated and detected.

[0096] As used herein, the term “purify”, “purification”, “purifying”, “separate”, or “separation” does not necessarily refer to removing all materials from a sample other than the analyte(s) of interest. Instead, “purify”, “purification”, “purifying”, “separate”, or “separation” may refer to a procedure that enriches the amount of one or more analytes of interest relative to other components in the sample that may interfere with detection of the analyte of interest. Samples may be purified by various means to allow removal of one or more interfering substances, e.g., one or more substances that would interfere with the detection of selected precursor ions and fragment ions by mass spectrometry.

[0097] As used herein, the term “reference interval” on a laboratory test may refer to a reference range or a reference value that represents expected values for a specific test. For example, the “reference interval” may refer to a range of values that encompass the central 95% of results in a population or subpopulation.

[0098] As used herein, the term “sample” may comprise any suitable test sample that may contain an analyte of interest. A sample may be a biological sample, that is, a sample obtained from any biological source, including, but not limited to, an animal, a cell culture, an organ culture. A sample may be obtained from a mammalian animal, including, but not limited to, a dog, a cat, a horse, a monkey, primate and human. A biological sample may include, but not limited to, blood, plasma, serum, urine, saliva, tear, cerebrospinal fluid, bile, perspiration, hair, muscle, organ, other body fluid or tissue samples. Such samples may be obtained, for example, from a patient; that is, a living person, male or female, presenting oneself in a clinical setting for diagnosis, prognosis, or treatment of a disease or condition. In some instances, a test sample may be a non-biological sample obtained from, for example, manufacture or laboratory settings where synthetic analytes of interest may be analyzed.

[0099] As used herein, the term “sample injection” may refer to introducing an aliquot of a single sample into an analytical instrument, for example a mass spectrometer. The introduction may occur directly or indirectly. An indirect sample injection may be accomplished, for example, by injecting anDocket No. J5363-26802aliquot of a sample into a HPLC or UPLC analytical column that is connected to a mass spectrometer in an on-line fashion.

[0100] As used herein, the term “same sample injection” with respect to multiple analyte analysis by mass spectrometry may indicate that the ions for two or more different analytes of interest are determined essentially simultaneously by measuring ions for the different analytes from the same (i.e., identical) sample injection.

[0101] As used herein, the term “selective ion monitoring” may refer to a detection mode for a mass spectrometric instrument in which only ions within a relatively narrow mass range, typically about one mass unit, are detected.

[0102] As used herein, the term “solid phase extraction” or “SPE” may refer to a process in which a chemical mixture is separated into components as a result of the affinity of components dissolved or suspended in a solution (i.e., mobile phase) for a solid through or around which the solution is passed (i.e., solid phase). In some instances, as the mobile phase passes through or around the solid phase, undesired components of the mobile phase may be retained by the solid phase resulting in a purification of the analyte in the mobile phase. In other instances, the analyte may be retained by the solid phase, allowing undesired components of the mobile phase to pass through or around the solid phase. In these instances, a second mobile phase may be then used to elute the retained analyte off of the solid phase for further processing or analysis.

[0103] As used herein, the term “surface enhanced laser desorption ionization” or “SELDI” may refer to another method in which a non-volatile sample is exposed to laser irradiation, which desorbs and ionizes analytes in the sample by various ionization pathways, including photoionization, protonation, deprotonation, and cluster decay. For SELDI, the sample is typically bound to a surface that preferentially retains one or more analytes of interest. As in MALDI, this process may also employ an energy-absorbing material to facilitate ionization.

[0104] As used herein, the term “ultra high-performance liquid chromatography” or “UHPLC” may refer to a liquid chromatography technique that uses smaller particle sizes and higher pressures compared to traditional high-performance liquid chromatography, resulting in faster, more efficient, and higher-resolution separations. In some embodiments, UPLC may use a 1.5 - 2 pm packing material and a chromatographic system that may operate at pressures of 6,000 - 15,000 psi range, whereas HPLC may use 3-5 pm packing material and operate at 2,000 - 4,000 psi. Due to the reduction in band broadening, better signal-to-noise ratios may be achieved and thus, an improved sensitivity.METHODS. SYSTEMS AND COMPUTER PROGRAMS. AND KITS FOR GSH ANALYSIS Methods

[0105] Some embodiments of the present disclosure provide methods for determining the presenceDocket No. J5363-26802or amount of GSH. GSH is an abundant cellular reducing agent, whose major biological function is mitigating oxidative damage to biological macromolecules. Glutathione is also important in the metabolism and excretion of xenobiotic compounds. Glutathione is consumed to maintain cells in a reduced condition. Consequently, glutathione levels in patient samples may be expected to be reduced or diminished in disease states where oxygen reactive species are involved, such as rheumatoid arthritis and atherosclerosis. Low glutathione levels have also been linked to reduced dopamine production in neurons, which suggests a relationship to dopamine based neurological disorders such as Parkinson’s disease. High levels of glutathione have been linked to chemotherapy resistance in cancer treatments. The methods, systems, and computer programs as described herein may measure total GSH level in patient samples for disease diagnosis and / or prognosis in clinical settings. In some embodiments, the methods may be automated and implemented by the systems and computer programs described herein, and thus, increasing the throughput of the measurements to fulfill expanding clinical needs.

[0106] Methods may be provided for determining presence or an amount of glutathione by mass spectrometry. An exemplary method may include subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the test sample using liquid chromatography; subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry; determining an amount of the one or more ions by mass spectrometry; and using the amount of the one or more ions to determine the amount of glutathione in the test sample.

[0107] Another exemplary method for determining presence or an amount of glutathione by mass spectrometry may include subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, adding one or more internal standards into the test sample, purifying the derivatized glutathione and the one or more internal standards from the test sample using liquid chromatography, subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry, determining an amount of the one or more glutathione ions by mass spectrometry, and using the amount of the one or more glutathione ions to determine an amount of glutathione in the test sample.

[0108] Methods may be provided for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay. An exemplary method may include obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction where the sample may contain glutathione, subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, purifying the derivatized glutathione from the patient sample using liquid chromatography, subjecting the derivatized glutathione to an ionization source under conditionsDocket No. J5363-26802suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry, determining an amount of the one or more ions by mass spectrometry, using the amount of the one or more ions to determine the amount of glutathione in the patient sample, and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0109] An exemplary method for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay may include obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction where the sample may contain glutathione, subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione, adding one or more internal standards into the patient sample, purifying the derivatized glutathione and the one or more internal standards from the patient sample using liquid chromatography, subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry, determining an amount of the one or more glutathione ions by mass spectrometry, and using the amount of the one or more glutathione ions to determine an amount of glutathione in the patient sample, and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0110] FIG. 1 depicts an exemplary workflow 100 for quantitative measurement of GSH in accordance with various embodiments of the present disclosure. A test sample that may contain GSH may be subject to reduction and derivatization to produce derivatized GSH (102). GSH contains a thiol (-SH) group that can be reversibly oxidized and form the dimer, GSSG. The reduction and derivatization may free up all available GSH in the test sample, thereby enabling the quantification of total GSH level. The derivatized GSH may be purified from the test sample using liquid chromatography (104), followed by quantitative analysis, for example, by mass spectrometry. The GSH may be subject to an ionization source to produce respective ions (106), which may be quantified by mass spectrometry (108). The amount of ions can be related to the amount of GSH in the test sample (110).

[0111] In some embodiments, the test sample may include a biological sample, including, but is not limited to, blood, plasma, serum, urine, oral fluid, saliva, tear, cerebrospinal fluid, other body fluid or tissue samples. Nonvolatile materials (e.g., salts, ion-pairing agents, proteins, endogenous compounds, drugs, and metabolites) in the sample may cause significant matrix effect and / or ion suppression. Besides sample matrix, coeluting compounds and crosstalk may also contribute to this effect. When mass spectrometry is used, these nonvolatile materials may change the efficiency of droplet formation or droplet evaporation, which in turn affects the amount of ion charged in the gas phase that ultimately reaches the detector of the mass spectrometer. The mass and charge ofDocket No. J5363-26802individual analytes may also be factors in making a compound a candidate for ion suppression or in making one compound a source of ion suppression for another. For example, molecules with higher mass may suppress the signal of smaller molecules, and more polar analytes may be more susceptible to suppression. Thus, the minimization of matrix effect and ion suppression, especially in complex matrices, may require sophisticated experimental design and optimization. Various embodiments of the present disclosure may provide effective sample extraction and / or improved chromatographic separation, for example, by modifying chromatographic conditions so that the analyte of interest elutes in a region where ion suppression is not observed. Some other embodiments of the present disclosure may minimize the matrix effect and ion suppression by changing ionization sources, optimizing mass spectrometer parameters, internal standards, and / or selecting suitable ion transitions as quantifiers and qualifiers.

[0112] In some embodiments, GSH in the test sample may be subject to a reducing reagent and a derivatizing reagent (102). The reducing reagent may reduce oxidized GSSG, other protein-GSH, Cysteine-GSH, etc. and thus, release GSH. The reducing reagent may be selected from a phosphinebased reducing reagent or a thiol-based reducing reagent. The phosphine-based reducing reagent may comprise tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, or tris(3-hydroxy propyl) phosph ine (THPP). The thiol-based reducing reagent may comprise tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or P-mercaptoethanol (BME). In one embodiment, TCEP may be added into a biological sample (e.g., whole blood) to produce reduced GSH in the sample. When whole blood samples are used, intra-red blood cell (intra-RBC) GSH may be measured. Red blood cells may be separated and lysed to obtain intra-RBC GSH for measurement.

[0113] The derivatizing reagent may block the thiol group of GSH and minimize its conversion to GSSG. In some embodiments, the derivatizing reagent comprises maleimide that allows alkylation of the sulfhydryl group of GSH, thereby producing GS-maleimide. The chemical structure of maleimide is as follows:R

[0114] where R is selected from methyl, ethyl, propyl, butyl, pentyl, or poly-ethylene glycols.

[0115] In some embodiments, the maleimide may comprise N-methylmaleimide, N-(l -phenylethyl) maleimide, or p-N,N'-phenylenebismaleimide. In some embodiments, the maleimide may comprise N-ethylmaleimide (NEM), and the derivatized GSH may comprise GS-NEM. NEM is cell permeable and can react quickly with GSH. In some embodiments, excessive maleimide may be added into the sample such as all GSH is converted to GSH-maleimide. Unlike some other methods that require removing excess maleimide by solvent extraction, the described methods herein may not requireDocket No. J5363-26802maleimide removal, thereby significantly improving the efficiency in sample preparation.

[0116] In some embodiments, the reducing reagent may be added into the sample followed by the derivatizing reagent. The reducing reagent may reduce GSSG in the sample to GSH, and the derivatizing reagent may block the thiol group of GSH. In this case, the amount of derivatized GSH may represent the amount of total GSH (i.e. , reduced and oxidized GSH) in the test sample. In other embodiments, the derivatizing reagent may be added immediately into the sample. For example, the derivatizing reagent may be added into a sample collection container (e.g., blood draw tube) such that when a sample is collected, GSH in the sample may be derivatized immediately. In this case, reduced GSH in the test sample may be converted to derivatized GSH, while oxidized GSH (e.g., GSSG) may remain unchanged. Both derivatized GSH (from reduced GSH) and oxidized GSH may be measured using the methods described herein. In addition, the GSH / GSSG ratio may be calculated using the methods described herein.

[0117] One or more internal standards may be added into the test sample. The internal standards may be isotopically labeled, for example, with one or more isotopes of D (2H),13C,15N,18O etc. The internal standards may comprise isotopically labeled GSH and / or maleimide. For example, the internal standards may be selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0118] The analyte of interest may be enriched relative to other components (e.g. protein) in the test sample during sample preparation. The enrichment methods may include filtration, centrifugation, thin layer chromatography (TLC), electrophoresis including capillary electrophoresis, affinity separations including immunoaffinity separations, extraction methods including ethyl acetate extraction and methanol extraction, and the use of chaotropic agents or any combination of the above or the like.

[0119] In some embodiments, the methods may further include extracting glutathione from the test sample prior to the purification. The extracting may include protein precipitation from the test sample. Protein precipitation may remove most protein from the test sample leaving analyte of interest in the supernatant. The sample may be centrifuged to separate the liquid supernatant from precipitated proteins. The resultant supernatant may then be applied to liquid chromatography and subsequent mass spectrometry analysis. In some embodiments, the use of protein precipitation, for example, protein precipitation using organic solvent (e.g., acetonitrile, acetone, methanol), may obviate the need for HTLC or other on-line extraction prior to HPLC and mass spectrometry. Accordingly, some embodiments described herein may include performing protein precipitation of the test sample; and loading the supernatant directly onto the HPLC-mass spectrometer without using on-line extraction or HTLC.

[0120] Instruments and columns for purification need to be selected to be suitable to purify the analyte of interest, for example, GSH as described herein. In some embodiments, a chromatographicDocket No. J5363-26802column may include a medium (e.g., a packing material) to facilitate separation of chemical moieties (e.g., functional groups of molecules). The medium may include minute particles made of e.g., silica or polymeric materials. The particles may include a bonded surface that interacts with various chemical moieties to facilitate separation of the chemical moieties of analytes to be quantified. The bonded surface may be coated with e.g., alkyl group, fluoroalkyl group, cyano group, amide group, amino group, dimethylamine group, quaternary amine group, sulfonic acid group, carboxylic acid group, diol group, or phenyl group. In some embodiments, an alkyl bonded surface may include C-4, C-8, or C-18 bonded alkyl groups. The chromatographic column may include an inlet port for receiving a sample and an outlet port for discharging an effluent that includes the fractionated sample. A sample may be applied to the chromatographic column at the inlet port, eluted with a solvent or solvent mixture, and discharged at the outlet port. Different solvent modes may be selected for eluting different analytes of interest. For example, liquid chromatography may be performed using gradient mode (e.g., with solvents of gradually changing proportions during the chromatographic run), or isocratic mode (e.g., with consistent solvent(s) throughout the chromatographic run).

[0121] In some embodiments, multiple LC systems may be used to achieve better purification results and higher efficiency. For example, HPLC, alone or in combination with one or more purification methods, may be used to purify the analyte of interest. In such embodiments the test sample may be extracted using an HPLC extraction cartridge which captures the analyte, then eluted and chromatographed on a second HPLC column or onto an analytical HPLC column prior to ionization. In some embodiments, multiple (e.g., 2, 3, 4, or more) parallel LC systems may be used via, for example, staggered injection, and coordinated by software programs. Because the steps involved in these chromatography procedures can be linked in an automated fashion, the requirement for operator involvement during the purification of the analyte can be minimized. This feature can result in savings of time and costs, and eliminate the opportunity for operator error.

[0122] Turbulent flow, such as that provided by HTLC columns and methods, may enhance the rate of mass transfer, improving separation characteristics. HTLC columns separate components by means of high chromatographic flow rates through a packed column containing rigid particles. By employing high flow rates (e.g., 3-5 mL / min), turbulent flow occurs in the column that causes nearly complete interaction between the stationary phase and the analyte(s) of interest. An advantage of using HTLC columns is that the macromolecular build-up associated with biological fluid matrices is avoided since the high molecular weight species are not retained under the turbulent flow conditions. HTLC methods that combine multiple separations in one procedure lessen the need for lengthy sample preparation and operate at a significantly greater speed. Such methods also achieve a separation performance superior to laminar flow (e.g., HPLC) chromatography. HTLC allows for direct injection of biological samples (plasma, urine, etc.). Direct injection is difficult to achieve in traditional forms of chromatography because denatured proteins and other biological debris quickly block theDocket No. J5363-26802separation columns. HTLC also allows for very low sample volume of less than 1 mL, preferably less than 0.5 mL, preferably less than 0.2 mL, preferably 0.1 mL. In some embodiments, samples may be subjected to protein precipitation as described above prior to loading on the HTLC column.Alternatively, the samples may be loaded directly onto the HTLC without being subjected to protein precipitation. The HTLC extraction column may be a large particle column.

[0123] HTLC may be followed by HPLC on a hydrophobic column chromatographic system. For example, a polymer-based column (60 pm particle size, 50x1.0 mm column dimensions, 100 A pore size) may be used. Alternatively, an ether-linked phenyl, analytical column (4 pm particle size, 150x2.0 mm column dimensions, 80 A pore size) with hydrophilic endcapping may be used.

[0124] In some embodiments, the analyte of interest may be purified by applying a test sample to a column under conditions where the analyte of interest is reversibly retained by the column packing material, while one or more other materials are not retained. In these embodiments, a first mobile phase condition can be employed where the analyte of interest is retained by the column, and a second mobile phase condition can subsequently be employed to remove retained material from the column, once the non-retained materials are washed through. Alternatively, an analyte may be purified by applying a sample to a column under mobile phase conditions where the analyte of interest elutes at a differential rate in comparison to one or more other materials. Such procedures may enrich the amount of one or more analytes of interest relative to one or more other components of the sample.

[0125] Optionally, the analyte of interest may be enriched or partly purified by liquid-liquid extraction (LLE) prior to HPLC. LLE may remove lipids and / or fibrinogen in the biological sample. Optionally, the analyte of interest may be enriched or partly purified by solid phase extraction (SPE). SPE may be an anion exchange solid-phase extraction. Alternatively, SPE may be a mixed-mode anion exchange solid-phase extraction.

[0126] In some embodiments, the test sample may be subjected to acidic conditions. For example, contacting the test sample with acidic conditions may include contacting the test sample with formic acid. In other embodiments, the test sample may be subjected to basic conditions. For example, contacting the test sample with basic conditions may include contacting the test sample with trizma. In other embodiments, contacting the test sample with basic conditions may include contacting the test sample with trizma and ethanol.

[0127] In some embodiments, the test sample may include blood, plasma, serum, urine, saliva, tear, cerebrospinal fluid, other body fluid or tissue samples. Nonvolatile materials (e.g., salts, ion-pairing agents, proteins, endogenous compounds, drugs, and metabolites) in the sample may cause significant matrix effect and / or ion suppression. Besides sample matrix, coeluting compounds and crosstalk may also contribute to this effect. When mass spectrometry is used, these nonvolatile materials may change the efficiency of droplet formation or droplet evaporation, which in turn affects the amount of charged ions in the gas phase that ultimately reaches the detector of the mass spectrometer. The massDocket No. J5363-26802and charge of individual analytes may also be factors in making a compound a candidate for ion suppression or in making one compound a source of ion suppression for another. For example, molecules with higher mass may suppress the signal of smaller molecules, and more polar analytes may be more susceptible to suppression. Thus, the minimization of matrix effect and ion suppression, especially in complex matrices, may require sophisticated experimental design and optimization. Various embodiments of the present disclosure may provide effective sample extraction (e.g., protein precipitation, solid phase extraction, liquid-liquid extraction) and / or improved chromatographic separation, for example, by modifying chromatographic conditions so that the analyte of interest elutes in a region where ion suppression is not observed. Some other embodiments of the present disclosure may minimize the matrix effect and ion suppression by changing ionization sources.

[0128] Referring back to FIG. 1 (e.g., 106, 108, and 110), the derivatized GSH may be ionized under an ionization source suitable to generate ions detectable by mass spectrometry. Mass spectrometry may be performed using a mass spectrometer that includes an ion source for ionizing the fractionated sample and creating charged molecules for further analysis. The ionization of the sample may be performed by electron ionization (El), chemical ionization (CI), heated electrospray ionization (HESI), electrospray ionization (ESI), photon ionization, atmospheric pressure chemical ionization (APCI), photoionization, atmospheric pressure photoionization (APPI), fast atom bombardment (FAB), liquid secondary ionization (LSI), matrix assisted laser desorption ionization (MALDI), field ionization, field desorption, thermospray / plasmaspray ionization, surface enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP) and particle beam ionization. The choice of ionization method may be determined based on the analyte to be measured, the type of sample, the type of detector, the choice of positive versus negative mode, etc. In some embodiments, the ionization of derivatized GSH may be performed by electrospray ionization (ESI), for example, heated electrospray ionization (HESI). In some embodiments, the ionization of derivatized GSH may be in positive ion mode.

[0129] After the analyte of interest is ionized, positively charged and / or negatively charged ions produced thereby may be analyzed to determine a mass-to-charge (mass / charge, or m / z) ratio. The amount of ions generated from the ionization may be detected and quantified using mass spectrometry (108 of FIG. 1). Based on the amount of GSH ions, the amount of GSH in the test sample may be determined (110 of FIG. 1). A mass spectrometer may provide an ion scan, that is, the relative abundance of each ion with a particular mass / charge over a given range (e.g., 100 to 1000 amu). The results of an analyte assay, that is, a mass spectrum, may be related to the amount of the analyte in the original sample. For example, given that sampling and analysis parameters are carefully controlled, the relative abundance of a given ion may be compared to a table that converts that relative abundance to an absolute amount of the original molecule. Alternatively, molecular standards may be run with the samples, and a standard curve constructed based on ions generated from those standards. UsingDocket No. J5363-26802such a standard curve, the relative abundance of a given ion may be converted into an absolute amount of the original molecule. In some embodiments, one or more internal standards may be used to generate a standard curve for calculating the quantity of the analyte. For example, an isotope of analyte, analyte derivative, or chemical compound with similar structures as the analyte may be used as an internal standard.

[0130] The resolution of MS may further be enhanced by employing tandem mass spectrometry, or MS / MS. In MS / MS, parent or precursor ions may be generated from a sample by a first MS procedure, and then fragmented to yield one or more product or fragment ions, which are subsequently analyzed by a second MS procedure. MS / MS can be useful for analyzing complex samples, especially biological samples, in part because the selectivity of MS / MS can minimize the need for extensive sample clean-up prior to analysis. In some embodiments, precursor ions may be generated from the test sample and passed through a first mass filter (quadrupole 1 or QI) to select those ions having particular mass-to-charge ratios. These precursor ions may be fragmented by, for example, collisions with neutral gas molecules in the second quadrupole (Q2), to yield product / fragment ions which are selected in the third quadrupole (Q3), the mass spectrum of which may be recorded by an electron multiplier detector. The two stages of mass filtering may eliminate ions from interfering species present in the conventional mass spectrum of a complex sample.Because both the precursor and fragment ions are produced in a reproducible fashion under a given set of ionization / fragmentation conditions, the MS / MS technique is a powerful analytical tool particularly for complex samples (e.g., biological samples).

[0131] GSH may be detected and / or quantified using MS / MS. The test sample may be subjected to liquid chromatography, for example, HPLC. The flow of liquid solvent from the chromatographic column may enter the heated nebulizer interface of an MS / MS analyzer, and the solvent / analyte mixture may be converted to vapor in the heated tubing of the interface. GSH may be ionized by the selected ionizer. The ions, e.g., precursor ions, may pass through the orifice of the instrument and enter the first quadrupole. Quadrupoles 1 and 3 (QI and Q3) may be mass filters, allowing selection of ions (i.e., “precursor” and “fragment” ions) based on their m / z ratios. Quadrupole 2 (Q2) may be the collision cell where ions are fragmented. The first quadrupole of the mass spectrometer (QI) may select molecules with the m / z ratio of GSH. Precursor ions with the correct m / z ratio may be allowed to pass into the collision chamber (Q2), while unwanted ions with any other m / z ratios may collide with the sides of the quadrupole and be eliminated. Precursor ions entering Q2 may collide with neutral argon gas molecules and fragment via collision activated dissociation. In this process, precursor ions may gain energy through collisions with an inert gas, and be subsequently fragmented by unimolecular decomposition. Sufficient energy must be deposited in the precursor ion so that certain bonds within the ion can be broken due to increased vibrational energy. In some embodiments, the collision energy may be within the range of about 10 eV to about 40 eV, about 10 eV to about 30Docket No. J5363-26802eV, about 10 eV to about 20 eV, about 5 eV to about 30 eV, about 5 eV to about 20 eV. In some embodiments, the collision energy may be within the range of about 10 eV to about 20 eV.

[0132] As ions collide with the detector, they produce a pulse of electrons that are converted to a digital signal. The acquired data may be relayed to a computer, which plots counts of the ions collected versus time, namely, mass chromatograms. The areas under the peaks corresponding to particular ions, or the amplitude of such peaks, are measured and the area or amplitude may be correlated to the amount of the analyte of interest. In some embodiments, the area under the curves, or amplitude of the peaks, for fragment ion(s) and / or precursor ions may be measured to determine the amount of analyte. As described above, the relative abundance of a given ion may be converted into an absolute amount of the original analyte, using calibration standard curves based on peaks of one or more ions of internal standards.

[0133] In various embodiments, multiple GSH precursor-fragment ion transitions may be measured. When GSH is derivatized by NEM producing GS-NEM, the ionization of GS-NEM may generate a GSH precursor ion with a m / z ratio of 433.2 ± 0.5, which is subsequently fragmented into fragment ions of m / z ratio of 304.1 ± 0.5 and 287.1 ± 0.5. The fragment ions may be selected for quantification of GSH. Alternatively or additionally, one or more fragment ions may be selected as qualifiers. For example, fragment ions with m / z ratio of 304.1 ± 0.5 may be used for quantification of GSH while fragment ions with m / z ratio of287.1 ± 0.5 used as qualifier. The use of qualifier peaks may ensure the identity of the analyte of interest, increase the specificity of the analyte and reduce the risk of misidentification.

[0134] Ion ratios ensures assay specificity with MS / MS methods, as deviations from expected values may be indicative of the presence of an interference or problems with ionization, detector sensitivity, or peak integration. In some of the LC-MS / MS methods, product ion transitions may be typically first identified from experiments using neat reference standards in a clean solvent. However, it is recognized herein that transitions identified under such idealized, “neat” conditions need to be verified and challenged in a different matrix. In many applications, ion ratios may be dependent on concentration, instrument status, types of analytes, and sample matrices. M. Vogeser and C. Seger, Pitfalls Associated with the Use of Liquid Chromatography-Tandem Mass Spectrometry in the Clinical Laboratory, Clinical Chemistry 56:8 1234-1244 (2010). In the scenario of using biological samples, matrix effect and ion suppression caused by endogenous components as well as interferences in the sample may further complicate the detection and quantification of ions corresponding to an analyte of interest. T. M. Annesley, Ion Suppression in Mass Spectrometry, Clinical Chemistry 49:7 1041-1044 (2003). Therefore, the identification, selection, and quantification of precursor and fragment ions may require sophisticated experimental design and optimization in sample preparation (e.g., enzymatic preparation, target analyte purification), chromatography (e.g., LC flow rate, solvent composition, column selection, ionization (e.g., collision energy), and more. Various embodiments ofDocket No. J5363-26802the present disclosure may select precursor GSH ions and / or fragment ions that provide optimized sensitivity and specificity, thereby enabling quantification of GSH in a complex matrix.

[0135] When one or more internal standards (IS) are added, the ionization may generate IS precursor ions which can be further fragmented into one or more IS fragment ions. For example,13C2-15N-glutathione-NEM-d5 may be used as IS, and the ionization may generate precursor ions with a m / z ratio of 441.0 ± 0.5, which is subsequently fragmented into fragment ions of m / z ratio of 312.0 ± 0.5.

[0136] The sample throughput may further be improved by column multiplexing, where multiple (e.g., two, three, four, or more) test samples may be run in parallel. In some embodiments, each test sample may involve a different derivatizing reagent of different masses. The results for each sample may be differentiated by the masses of characteristic fragments of the derivatization agents, thereby providing multiple results in a single essay. For example, GSH in patient sample A may be derivatized using13C-maleimide to form GSH-13C-maleimide, and GSH in patient sample B may be derivatized using15N-maleimide to form GSH-15N-maleimide. Thus, GSH in patient samples A and B can be detected and differentiated when the samples are mixed. It should be noted that the derivatizing reagents described herein are exemplary without limiting the scope of the present disclosure.

[0137] The methods as described may be performed in an on-line, automated fashion, from GSH derivatization, purification, ionization, to quantification using mass spectrometry, which significantly simplifies the workflow and increases the throughput. In some embodiments, GSH derivatization may be performed using automatic liquid handling system. In some embodiments, one or more purification steps may be performed on-line. Preferably, all of the purification and mass spectrometry steps may be performed in an on-line fashion. For example, by careful selection of valves and connector plumbing, two or more chromatography columns may be connected as needed such that material is passed from one to the next without the need for any manual steps. The selection of valves and pumps may be controlled by a computer pre-programmed to perform the necessary steps. The chromatography system may also be connected in an on-line fashion to the detector system, e.g., an MS system. Thus, an operator may place a tray of samples in an autosampler, and the remaining operations are performed under computer control, resulting in purification and analysis of all samples selected.Systems and Computer Programs

[0138] Accordingly, one aspect of the present disclosure includes a system for determining presence or an amount of glutathione in a test sample using mass spectrometry. The system may include a reaction station for derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, a purification station for purifying the derivatized glutathione from the test sample by liquid chromatography, and a mass spectrometry station for ionizing the derivatized glutathione to generate one or more ions, and determine an amount of the one or more ions, where the amount of the one or more ions is related to presence or an amount ofDocket No. J5363-26802glutathione in the test sample. Another aspect of the present disclosure is non-transitory computer readable storage medium storing instructions (e.g., software program) that, when executed by at least one processor, cause a computing system to perform various methods as described herein.

[0139] FIG. 2 depicts an exemplary system 200 for quantitative measurement of GSH in accordance with various embodiments of the present disclosure. The system 200 may include a reaction station 202 where GSH in the test samples is aliquoted into sampling containers, derivatized, and / or separated; a purification station 204 for purifying GSH by, for example, liquid chromatography; a mass spectrometry station 210 for ionizing GSH, detecting and quantifying GSH ions; and a computer system 206 that communicates with one or more stations via wired or wireless communication. The system 200 may be on-line or automated with high efficiency, high reliability and minimum operator intervention, thereby increasing sample throughput.

[0140] The reaction station 202 may aliquot one or more test samples that contain GSH into sampling containers. The reaction station 202 may comprise a station for receiving one or more samples. The samples may comprise patient samples suspected of containing GSH. The reaction station 202 may automatically add one or more reagents (e.g., reducing reagent, derivatizing reagent, protein precipitation reagent, solvent) into the sample. Accordingly, the station 202 may include receptacles to discard the portion of the sample that is not used in the analysis. The reaction station 202 may further include a station for adding internal standards. Some of the internal standards may be isotopically labeled, thus, the station 202 may include safety features to facilitate the addition of internal standards into the sample.

[0141] The reaction station 202 may include a control system (e.g., central processing unit, CPU) that controls pipetting, dispensing, mixing, waste removing, and other liquid handling functions, a data processing unit for data recording and processing, memory for data storage, and / or communication interface. In some embodiments, the reaction station 202 may include an automated liquid handler for dispensing samples and reagents.

[0142] The purification station 204 may comprise one or more columns providing a stationary phase and containers / receptacles / reservoir containing solvents used as a mobile phase. An injector in the station 204 may introduce the test sample into the mobile phase. Pumps, lines, and valves contained in the station 204 may deliver and adjust the amount of each solvent applied to the column(s). The purification station 204 may also include a solvent waste system with a cap adapter or manifold that connects to a waste line, and a carbon filter that traps volatile organic solvent.

[0143] The purification station 204 may include one or more liquid chromatography systems (e.g., HPLC, HTLC, or the like). In some embodiments, HPLC may include a quaternary pump with a multichannel gradient valve for low-pressure mixing of solvents, a diode array detector that measures the ultraviolet and visible absorption spectra of chemicals eluted from the column(s), a degasser that removes dissolved gases from the mobile phase, an autosampler that automates the sample injection, aDocket No. J5363-26802column compartment, and a solvent tray. Sample may be reconstituted in acetonitrile in reagent grade water prior to application to HPLC column. In other embodiments, HTLC may include a quaternary pump, a binary pump for high-pressure mixing of solvents, a degasser, a column compartment, and a solvent tray.

[0144] Referring to some of the aforementioned embodiments, HPLC may optionally be used in combination of other extraction systems, for example, LLE or SPE. Accordingly, an LLE or SPE cartridge / column may be included in the reaction station 202 or purification station 204. In some embodiments, the reaction station 202 or purification station 204 may include an automated LLE system.

[0145] The purification station 204 may have a control station and data processing unit for controlling various functions of the station as described above, as well as module (e.g., autosampler, pumps, detectors, degasser) controlling, data recording, processing, and storage. In some embodiments, the purification station 204 may include a computer system for data acquisition and processing, chromatogram generation, sample component identification and quantification, and controlling components / modules in the station (e.g., pump, autosampler, detector).

[0146] Referring back to FIG. 2, the system 200 may also include amass spectrometry station 210 containing an ionization source 212, a mass analyzer 214, a detector 216 that are connected to a control station 218. When the purified and derivatized GSH is introduced into the mass spectrometry station 210, it may be detected and quantified based on the amount of GSH ions generated.

[0147] The ionization source 212 may produce gas phase ions suitable for resolution in the mass analyzer 214. The ionization source 212 may perform El, CI, HESI, ESI, photon ionization, APCI, photoionization, APPI, FAB, LSI, MALDI, field ionization, field desorption, thermospray / plasmaspray ionization, SELDI, ICP, or particle beam ionization. The ionization source 212 may ionize GSH in positive or negative ion mode. In some embodiments, the ionization source 212 may be electrospray ionization (ESI), for example, heated electrospray ionization (HESI). The ionization source 212 may be in positive ion mode.

[0148] The mass analyzer 214 may separate ions produced by the ionization source 212 based on their m / z ratio, allowing for the identification and quantification of analyte of interest in the sample. Ions with different m / z ratios may be accelerated and passed through the mass analyzer 214 and sorted. Suitable analyzers for determining m / z ratios may include quadrupole analyzers, ion traps analyzers, orbitrap analyzers, and time-of-flight analyzers. The ions may be detected using different detection modes. For example, selected ions may be detected using a selective ion monitoring mode (SIM). Alternatively, ions may be detected using a scanning mode, e.g., multiple reaction monitoring (MRM) or selected reaction monitoring (SRM). In some embodiments, m / z ratios may be determined using a quadrupole analyzer. For example, in a “quadrupole” or “quadrupole ion trap” instrument, ions in an oscillating radio frequency field experience a force proportional to the DC potential appliedDocket No. J5363-26802between electrodes, the amplitude of the RF signal, and the m / z ratio. The voltage and amplitude may be selected so that only ions having a particular m / z ratio travel the length of the quadrupole, while all other ions are deflected. Thus, quadrupole instruments may act as both a “mass filter” and as a “mass detector” for the ions injected into the instrument. In some embodiments, the mass spectrometry station 210 may include a tandem mass spectrometry (MS / MS) system, which can be a triple quadrupole mass spectrometer. GSH may be quantified based on the amount of the characteristic transitions of ions by MS / MS. In a triple quadrupole MS / MS system, the first and third quadrupole mass analyzers (QI and Q3) may be used as mass analyzers and the middle quadrupole (Q2) as a collision chamber.

[0149] The ion detector 216 may detect mass-separated ions and convert their presence into measurable signals in the form of an electrical current or count of ions. The signals may be processed to generate a mass spectrum that correlates ion abundance with m / z ratios. The detector 216 may be an electron multiplier, a Faraday cup, an array detector, or a photomultiplier conversion dynode (including a microchannel plate and a scintillator).

[0150] As illustrated in FIG. 2, the mass spectrometry station 210 may include a control station 218 for instrument operation, data acquisition, processing, and storage. The control station 218 may include a central processing unit or data processing unit, and / or non-transitory computer readable storage medium containing instructions that, when executed on the central processing unit or data processing unit, cause the unit to implement various embodiments as described herein.

[0151] The purification station 204 and mass spectrometry station 210 may be connected to the computer 206. Optionally, the reaction station 202 may also be connected to the computer 206. These connections may be wired or wireless. In some embodiments, the computer 206 may include software programs that control the automation process from sample preparation, purification, ionization, to GSH quantification. For example, the computer 206 may control various components of the modules (202, 204, and 210), for example, pumps, valves, autosamplers. Thus, the system 202 may be highly automated, thereby increasing sample throughput and minimizing operator intervention.

[0152] In some embodiments, the computer 206 may include software programs for complex data calculation and interpretation. As the mass spectrometry station 210 may have fast scanning speed, more mass spectra will be collected and require interpretation to identify chemical formulas with characteristic peaks. Accordingly, the computer 206 may include or have access to one or more algorithms, databases, and reference libraries for data analysis. For example, the computer 206 may include software programs or have access to algorithms for both interpreting and predicting patterns in the MS data. The MS data describing precursor-to-product transitions may be filtered against a set of thresholds, where the filtering may depend on integrated peak area, relative area, signal-to-background, retention time, etc. Some of the MS data may be annotated (e.g., preprocessing, featurization) and be used as training or validation data. The preprocessing may includeDocket No. J5363-26802normalization, scaling, or encoding. In some embodiment, the preprocessing may be accomplished by employing isotopically labeled internal standards. The featurization may transform original MS spectra into variables or formats that the algorithms can process, by, for example, binning m / z abundance values and vectorizing analyte topology via molecular fingerprinting. The MS data may further be analyzed for peak annotation, determination of compound elemental compositions, structural classifications or predictions, and mass spectral classifications or predictions. For example, the computer 206 may include or have access to machine learning algorithms that use binned m / z values as input and output the likelihood of respective molecular fingerprint (e.g., functional groups) of an analyte of interest. In addition, the computer 206 may include software programs or have access to algorithms for classifying patient samples for clinical diagnosis, based on analysis of the respective MS data of the samples.

[0153] In other embodiments, the computer 206 may include or have access to one or more software programs for automation, thereby streamlining workflows, reducing turnaround time, and seamlessly scaling operations. The software programs may control automated handling small-volume and / or delicate samples, accurate operation of various components and modules of the system 200, and predicting assay time (e.g., how long the mass spectrometry station 210 would take to acquire data as a function of retention time).

[0154] The software programs may include one or more of statistical, machine learning, and / or deep learning models for data processing, analyte of interest classification / prediction, and / or system automation. The models may include linear and logistic regression models, support vector machines, decision trees, random forest, embedding models (e.g., principal component analysis, t-distributed stochastic neighbor embedding, uniform manifold approximation and projection), clustering models (e.g., k-means clustering, Gaussian mixture models, k-nearest neighbors), neural networks (e.g., convolutional neural networks, recurrent neural networks, autoencoders, transformers, multilayer perceptron). The models may work in a supervised, semi-supervised, or unsupervised manners. For example, supervised models may use annotated MS data, where the annotation may include peak heights, sample identity, peak classification, etc. On the other hand, semi-supervised and unsupervised models may use unannotated MS data for data clustering and dimensionality reduction. Multiple models may be used together (by e.g., boosting, or stacking) to achieve ensemble learning with increased accuracy and reduced risk of overfitting.

[0155] The computer 206 may include at least one central processing unit (CPU) that communicates with a number of peripheral devices via bus subsystem. The peripheral devices may include, but not limited to, a storage subsystem including, for example, memory devices and a file storage subsystem, user interface input devices, user interface output devices, and a network interface subsystem. The storage subsystem may store programming and data constructs that provide the functionality of the methods described herein. The memory devices may include one or more of a main random accessDocket No. J5363-26802memory (RAM) for storage of instructions and data during program execution and a read only memory (ROM) in which fixed instructions are stored. The input and output devices may allow user interaction with the computer system. Network interface subsystem may provide an interface to outside networks, including an interface to corresponding interface devices in other computer systems. In other embodiments, the computer 206 may include at least one graphics processing units (GPUs), field-programmable gate arrays (FPGAs), application-specific integrated circuits (ASICs), and / or coarse-grained reconfigurable architectures (CGRAs).

[0156] It should be noted that although some or all of the steps in the methods and the stations may be performed on-line, in certain embodiments, some of the steps may be performed off-line.Kits

[0157] Another aspect of the present disclosure is a kit for GSH quantification assay. A kit for GSH quantification assay may comprise compositions including an isotopically labeled internal standard, in an amount sufficient for at least one assay. In some embodiments, the kit may also include instructions recorded in a tangible form (e.g., contained on paper or an electronic medium) for using the packaged reagents for preparation for use in an assay, e.g, in the GSH quantification assay described herein. In some embodiments, the kit further comprises packaging material. In some embodiments, the one or more isotopically labeled internal are labeled with one or more deuterium (2H),13C, and / or15N atoms. In some embodiments, the one or more internal standards may be selected from the group consisting ofN-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, and13C2-15N-glutathione-NEM-d5.

[0158] Quality control (QC) pools having known concentrations, for use in embodiments of the present invention, are preferably prepared using a matrix similar to the intended sample matrix. In some embodiments, the kit comprises an internal standard diluted in a solvent (e.g., ethanol).

[0159] The internal standard for GSH quantification may comprise an isotopologue compound of GSH (e.g., a compound with identical or substantially similar chemical composition and structure of GSH, but with one or more of the naturally occurring atoms being replaced with sufficient stable isotopes as to create a standard with sufficient mass to discriminate between the internal standard and the naturally occurring analyte of interest.) In some embodiments, the internal standard in the kit may include GSH labeled with at least one or more of D (2H),13C,15N, or18O.

[0160] In some embodiments, the internal standard in the kit may include one or more of N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5. In some other embodiments,, the internal standard in the kit may include GSH (glycine-13C-15N), where the glycine moiety of the glutathione molecule may be labeled with one13C and one15N; or GSH (glycine-13C2-15N), where the glycine moiety of the glutathione molecule may be labeled with two13C and one15N. Another example of internal standard in the kit may include GSH (cysteinyl-13C3), where the cysteine moiety of the glutathione molecule may be labeled with three13C.Docket No. J5363-26802

[0161] In other embodiments, the determination of total glutathione may include quantitative reduction of all oxidized glutathione. Accordingly, the internal standard in the kit may include a stable isotope-labeled isotopologue of GSSG. When determining the total glutathione, all GSSG may be reduced to GSH during sample preparation. A labeled GSSG standard may be stoichiometrically converted to labeled GSH, making it an effective internal standard. Examples of such compounds may include GSSG (glycine-13C,15N), where the glycine moieties of the GSSG may be labeled with one13C and one15N, or glutathione disulfide (glycine-13C2,15N), where the glycine moieties of the GSSG may be labeled with two13C and one15N. Another example may include glutathione disulfide (cysteinyl-13C3), where the cysteine moiety of the GSSG dimer may be labeled with three13C. As glutathione is a tripeptide of glutamate, cysteine and glycine, the GSH and GSSG internal standards described in the aforementioned embodiments are for exemplary purposes without limiting the scope of the disclosure. The types, numbers, and locations of the isotopic labels are not limited by these examples.

[0162] Embodiments as described herein may have numerous advantages. For example, accurate and precise LC-MS / MS and / or HPLC-MS / MS methods have been developed to allow quantitative measurement of GSH in patient samples. The analytical measurement range (AMR) and clinical reportable range (CRR) are greater than currently reported ranges. The systems and methods can be on-line or highly automated, significantly increasing the sample throughput. The specificity and sensitivity provided by the disclosed systems and methods may allow detection and / or quantification of GSH in complex samples, including, but not limited to blood, plasma, serum, urine, saliva, tear, cerebrospinal fluid, other body fluid or tissue samples.

[0163] As an example, various embodiments as described herein may enable the clinical evaluation of oxidative stress, a condition characterized by an imbalance between the production of free radicals and the body's ability to neutralize them. GSH is an important marker of oxidative stress. Under certain conditions, human body produces more reactive oxygen species, which decrease intracellular defenses against oxidation, for instance intra RBC glutathione. Lower levels of intra red blood cell GSH is an important marker of chronic diseases (e.g., diabetes, cancer, cardiovascular disease) and of unhealthy aging. The accurate detection and quantification of GSH as described in various embodiments may provide a diagnostic basis for oxidative stress and associated diseases or other unhealthy conditions.EXAMPLES

[0164] Examples described herein are to provide guidance to those skilled in the art for practicing representative embodiments in the present disclosure. Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter.Docket No. J5363-26802

[0165] An analytical method was developed and validated for total GSH measurement in whole blood samples via LC-MS / MS, in accordance with various embodiments of the present disclosure. The results, as described below in more details, showed that the average instrument precision was well below 6.25% (one fourth of total allowable error (TEa) or TEa / 4). The average total precision was well within 8.7% (one third of Tea or TEa / 3). The average recovery was approximately 105.2%. The linearity was verified across known physiological range of all reported parameters. The analytical measurement range (AMR) and clinical reportable range (CRR) were 0.1 mmol / L to 10 mmol / L. No significant carryover effect was observed. Thus, the method was validated to be acceptable for clinical testing.Example 1. Sample Preparation and GSH purification

[0166] Whole blood patient samples were collected in lavender top tubes with EDTA, stored at room temperature (RT) for less than or equal to 24 hours, or refrigerated for less than or equal to 72 hours.20 pL whole blood was pipetted into sample container 1 (e.g., deep well plate), followed by addition of 180 pL of TCEP working solution (10 mmol / L in water). The mixture needed to be shaking at 1200 RPM for 15 minutes at room temperature. Subsequently, 200 pL of NEM working solution (20 mmol / L NEM and 2 mmol / L EDTA in phosphate buffered saline (PBS)) was added into the mixture and shaken at 1200 RPM for 15 minutes at room temperature to produce GS-NEM. 50 pL of the mixed solution was pipetted into sample container 2. 150 pL of internal standard working solution (4 pmol / L13C2-15N-Glutathione-NEM-d5 in acetonitrile) into the mixed solution and shaken at 1200 RPM for 2 minutes at room temperature. The protein in the sample was precipitated, followed by centrifuging at 3000 RPM for 10 minutes at room temperature. 40 pL of the supernatant was removed and pipetted into sample container 3. 560 pL of water with 0.1% formic acid was added, shaking at 1000 RPM for 5 minutes at room temperature, followed by centrifuging at 3000 RPM for 10 minutes at room temperature to remove remaining interfering substances in the sample. The produced solution was placed into autosampler for further purification. All sample preparation steps could be handled by Hamilton MicroLab Star liquid handler. Alternatively, one or more steps could be done manually.

[0167] Agilent 1200 serial HPLC system and Agilent Infinity 1260 HiP ALS standard autosampler were used for GS-NEM purification. Alternatively, Agilent StreamSelect LC / MS system can be used for multiple sample testing. The injection volume of the sample was 5 pL. The draw speed and eject speed of the autosampler were 200 pL / min. For HPLC, 0.1% formic acid in water was used as mobile phase A, and 0.1% formic acid in acetonitrile used as mobile phase B. As a result, GS-NEM and internal standards were extracted from the samples.Example 2. Quantitation of GSH by MS / MS

[0168] The extracted GS-NEM and internal standards were ionized and quantified by MS / MS. Agilent Jet Stream electrospray source was used as ionization source. Alternatively, equivalentDocket No. J5363-26802ionization source can be used. The ionization source was in positive ion mode. Agilent 6490A Triple Quadrupole Mass Spectrometer was used. Alternatively, equivalent MS systems can be used. Multiple reaction monitoring (MRM) was used for scanning.

[0169] FIG. 3A depicts an exemplary chromatogram of derivatized GSH with respective counts in accordance with various embodiments of the present disclosure. FIG. 3B depicts an exemplary chromatogram of derivatized GSH with respective relative abundance in accordance with various embodiments of the present disclosure. The GS-NEM eluted two separate peaks representing two diastereoisomers with different physical and chemical properties. Either of the two peaks or integration of both peaks can be used for the GSH measurement. As illustrated, derivatized GSH (e.g., GS-NEM) was ionized and produced precursor ions with m / z ratio of 433.2 ± 0.5, which transited into fragment ions with m / z ratios of 304.1 ± 0.5 and 287.1 ± 0.5 (ratio 72.7%). In this example, fragment ions with m / z ratio of 304.1 ± 0.5 was used as quantifier peaks, whereas fragment ions with m / z ratio of287.1 ± 0.5 was used as qualifier peaks.

[0170] FIG. 4A depicts an exemplary chromatogram of internal standard with respective counts in accordance with various embodiments of the present disclosure. FIG. 4B depicts an exemplary chromatogram of internal standard with respective relative abundance in accordance with various embodiments of the present disclosure. As illustrated,13C2-15N-Glutathione-NEM-d5 was ionized and produced precursor ions with m / z ratio of 441.0 ± 0.5, which transited into fragment ions with m / z ratios of 312.0 ± 0.5.

[0171] Calibrators were prepared using the same procedure as patient samples. GSH calibrators were prepared with six different concentrations using GSH stock solution and water (containing 0.1% formic acid), namely, Cal 1 (0.1 mmol / L), Cal 2 (0.2 mmol / L), Cal 3 (0.5 mmol / L), Cal 4 (2 mmol / L), Cal 5 (5 mmol / L), and Cal 6 (10 mmol / L). The tolerance limit for calibration was that the back-calculated values found for each calibrator should be within 15% of nominal, 20% at the lower limit of quantification (LLOQ). FIG. 5 depicts an exemplary calibration curve for quantitative measurement of GSH in accordance with various embodiments of the present disclosure using Cal 1 -Cal 6 solutions (y = 3.0872 * x - 0.009214, R2= 0.9997). The calibration curve met the acceptance criteria.

[0172] Different concentrations of quality control (QC) for GSH measurement were also prepared, including ultra-low QC (0.2-0.4 mmol / L), low QC (0.6-0.8 mmol / L), middle QC (1-1.3 mmol / L), and high QC (5-9 mmol / L). The ultra-low QC was prepared by adding 10 mL of whole blood to 10 mL of 1 x PBS, and aliquoting 0.3 mL into 13x100 mm specimen tubes. Low QC was prepared by pooling 20 mL of whole blood and aliquoting 0.3 mL into 13x100 mm specimen tubes. Middle QC was prepared by pooling 20 mL of whole blood, adding 0.12 mL GSH stock solution (100 mmol / L), and aliquoting 0.3 mL into 13x100 mm specimen tubes. High QC was prepared by pooling 20 mL of whole blood, adding 1.5 mL GSH stock solution, and aliquoting 0.3 mL into 13x100 mm specimenDocket No. J5363-26802tubes. All QC solutions were under thorough mixing throughout the analytical runs. All QC levels were analyzed in each analytical run (i.e., batch). For acceptable QC, the tolerance limits for standard deviation (SD) should not exceed one-third of total allowable error (TEa / 3).Example 3. Precision and Accuracy

[0173] Intra-assay precision assesses how closely results agree when the same sample is measured repeatedly in the same assay run. Here, the intra-assay (within run) variation was determined from testing twenty replicates of each of four pooled, whole blood samples. The results were used to determine the mean, standard deviation (SD), and coefficient of variation (CV). Acceptance criteria for the intra-assay precision was the samples should exhibit precision of TEa / 4 lower than or equal to 6.25%, and the Sigma higher than or equal to 4.0.

[0174] Table 1 shows intra-assay precision. As listed, the four pooled samples (i.e., Samples 01-04) showed CV of 2.7%, 1.8%, 2.7%, and 2.4%, respectively. The sigma for each of the four pooled samples was determined as 9.21, 14. 28, 9.20, and 10.35, respectively. The GSH measurement met acceptable reproducibility requirements of TEa / 4 (6.25%) and Sigma of 4.0 for precision.

[0175] Table 1. Intra-assay precisionGSH Sample Sample Sample Sample(mmol / L) 01 02 03 041 0.44 0.83 1.22 7.732 0.44 0.83 1.21 7.793 0.44 0.82 1.22 7.94 0.44 0.81 1.19 7.785 0.43 0.81 1.14 7.716 0.42 0.84 1.17 7.647 0.44 0.85 1.18 7.688 0.45 0.83 1.21 7.79 0.43 0.81 1.19 7.5810 0.44 0.82 1.15 7.7411 0.43 0.85 1.19 7.6312 0.44 0.84 1.21 7.7713 0.45 0.85 1.15 7.4314 0.41 0.83 1.22 7.5915 0.41 0.83 1.18 7.2116 0.43 0.83 1.15 7.4217 0.42 0.83 1.26 7.3618 0.42 0.82 1.24 7.5319 0.42 0.87 1.22 7.7820 0.41 0.84 1.16 7.32Average 0.43 0.83 1.19 7.62SD 0.01 0.01 0.03 0.18% CV 2.70% 1.80% 2.70% 2.40%Docket No. J5363-26802SigmaOverall 9.21 14.28 9.2 10.35Precision? YES YES YES YES

[0176] The inter-assay precision assesses how closely results agree when a sample is measured in multiple assay runs. Here, four samples were analyzed in five replicates on twenty runs across eleven days. Acceptance criteria for the intra-assay precision was the samples should exhibit precision of TEa / 3 lower than or equal to 8.3%, and the Sigma higher than or equal to 3.0.

[0177] Table 2 shows inter-assay precision. As listed, the four samples (i.e., Sample 1-4) showed total CV of 3.3%, 3.2%, 2.7%, and 3.2%, respectively. The overall Sigma for each sample was determined as 7.64, 7.73, 9.34, and 7.70, respectively. The GSH measurement met acceptable reproducibility requirements of TEa / 3 (8.3%) and Sigma of 3.0 for precision.

[0178] Table 2. Inter-assay precisionSample Sample Sample SampleSummary 1 2 3 4Count 100 100 100 100Grand Mean 0.4372 0.8468 1.208 7.667Average within-run SD 0.0068 0.0148 0.024 0.148Average within-run CV 1.6% 1.8% 2.0% 1.9%Total SD 0.0143 0.0274 0.032 0.249Total CV 3.3% 3.2% 2.7% 3.2%Sigma Overall 7.64 7.73 9.34 7.70Precision >= 3.0 sigma? YES YES YES YES

[0179] Accuracy was measured by spiking a calculated volume of solution containing known concentrations of GSH (i.e., spike recovery test). Whole blood samples were measured without additional GSH and then spiked with known concentrations of GSH. Average recoveries were determined by dividing the measured concentration of spiked GSH minus measured concentration of unspiked sample and dividing by the known spiked levels.

[0180] Table 3 lists the spike recovery results. Six unspiked samples were firstly measured for GSH concentration, each measurement was repeated four times, with the mean of 0.60 mmol / L, 0.48 mmol / L, 0.47 mmol / L, 0.40 mmol / L, 0.65 mmol / L, and 0.86 mmol / L, respectively. The samples were then spiked with known concentrations (1.00 mmol / L) of GSH and measured again. Each measurement was repeated four times. The measured concentration for each sample after spike was 1.64 mmol / L, 1.52 mmol / L, 1.54 mmol / L, 1.44 mmol / L, 1.69 mmol / L, 1.95 mmol / L, respectively. The recovery rate was 104.4%, 104.1%, 106.8%, 103.7%, 103.8%, 108.6%, respectively. The average recovery was 105.2%, and within TEa / 4 of 6.25%.

[0181] Table 3. Spike Recovery of Test Samples.Date of Analysis Measured Un-Spiked Sample Concentrations (mmol / L)Docket No. J5363-2680205 / 30 / 24 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 GSH 0.61 0.48 0.47 0.40 0.68 0.88 Concentrations 0.59 0.48 0.48 0.41 0.64 0.84 of Ln-Spiked 0.61 0.48 0.48 0.41 0.65 0.88 Samples 0.58 0.48 0.46 0.40 0.64 0.85 Mean of Un- 0.60 0.48 0.47 0.40 0.65 0.86 Spiked SamplesSD 0.02 0.00 0.01 0.00 0.02 0.02 CV 2.6% 0.6% 1.6% 1.0% 2.7% 2.0% Replicates 4 4 4 4 4 4Measured Spiked Sample Concentrations (mmol / L)Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Spiked Cone.(mmol / L) 1.00 1.00 1.00 1.00 1.00 1.00 GSH 1.62 1.47 1.57 1.42 1.71 2.02 Concentrations 1.65 1.52 1.55 1.48 1.71 1.93 of Spiked 1.64 1.53 1.51 1.43 1.66 1.96 Samples 1.66 1.57 1.52 1.42 1.68 1.89 Mean of Spiked1.64 1.52 1.54 1.44 1.69 1.95 SamplesSD 0.01 0.04 0.03 0.03 0.02 0.06 CV 0.8% 2.8% 1.8% 2.0% 1.4% 3.0% Replicates 4 4 4 4 4 4Spike Recovery 104.4% 104.1% 106.8% 103.7% 103.8% 108.6% Spike Recovery = ((Mean of Spiked- Mean of Un- Spiked) / Spiked Cone.)Example 3. Analytical Measurement Range (AMR)

[0182] Pooled, whole blood samples were spiked with increasing amount of GSH standard solutions and then measured via LCMS. Observed concentrations of GSH were then compared with respective predicted levels to verify the linearity of the assay. Acceptance criteria for verification was TEa / 4 for three replicates.

[0183] FIG. 6 depicts an exemplary analytical measurement range (AMR) for quantitative measurement of GSH in accordance with various embodiments of the present disclosure. Table 4 also lists the AMR evaluation of eight samples with different concentrations of GSH. Each measurement was repeated three times. As illustrated, total GSH measurement range was verified from 0.1 mmol / L to 10 mmol / L (y = 0.997x - 0.016), with LL, mid-point, and UL recovered. The clinical reportable range (CRR) was verified from 0.1 mmol / L to 10 mmol / L. This range covers reported values for GSH in whole blood (typically 0.5 mmol / L - 2 mmol / L). Moreover, the reported linearity has been verified across ranges significantly greater than previously reported ranges for whole blood samples. See, e.g., R. L. G. Norris, et al. , Journal of Chromatography B 2012, 898: 136-140; T. Moore, et al., Journal of Chromatography B 2013, 929: 51-55; I. Squellerio, et al. , Journal of Pharmaceutical and BiomedicalDocket No. J5363-26802Analysis 2012, 71 : 111-118; D. Giustarini, et al., Free Radical Biology & Medicine 2003, 35: 1365- 1372; and X. Fu, et al., Scientific Reports 2019, 9: 115.

[0184] Table 4. AMR VerificationTEa: 25.05% or 0.05 mmol / Lw / i Sample Target Repl Rep2 Rep3 Avg TEa / 4 min max Index range1 0.089 0.096 0.095 0.096 0.096 0.025 0.064 0.114 YES 26% 2 0.178 0.179 0.183 0.181 0.181 0.025 0.153 0.203 YES 12% 3 0.356 0.342 0.354 0.350 0.349 0.025 0.331 0.381 YES -30% 4 0.712 0.678 0.713 0.719 0.703 0.045 0.668 0.757 YES -20% 5 1.424 1.385 1.417 1.476 1.426 0.089 1.335 1.513 YES 2% 6 2.849 2.734 2.756 2.814 2.768 0.178 2.671 3.027 YES -45% 7 5.698 5.578 5.590 5.629 5.599 0.356 5.342 6.054 YES -28%8 11.395 11.494 11.346 11.345 11.395 0.712 10.683 12.107 YES 0%Example 4. Analytical Specificity

[0185] Various interfering substances were added into samples to measure the analytical specificity of the method. The interfering substances may be present in healthy or diseased states, and the concentration of the interfering substances may vary (e.g., elevate) depending on the physiological conditions of patients. Therefore, it is important to evaluate the analytical specificity of the assay for GSH measurement.

[0186] Lipemia is the presence of excessive amounts of lipid particles in the blood. Accordingly, the specificity of the assay was evaluated against lipemia. Intralipid was added into whole blood samples at concentrations of 0, 31, 62, 125, 250, 500 and 1000 mg / dL, where the whole blood samples contained low (~0.4 mmol / L) or high (-1.4 mmol / L) concentration of GSH.

[0187] Table 5A lists the specificity of the assay at low GSH concentration (-0.4 mmol / L) in the presence of different concentrations of intralipid. The GSH measurement for all the samples was in the range of 0.38-0.42, regardless the presence or concentration of intralipid. No analytical interference was observed.

[0188] Table 5A. Analytical Interferences - Lipemia, GSH Low ConcentrationIcterus - GSH Low ConcentrationBilrubin (mg / dL) 0 2.5 5 10 20 401 0.3982 0.4055 0.3829 0.3877 0.3871 0.36652 0.3839 0.4005 0.3961 0.3961 0.3819 0.37773 0.4000 0.4109 0.4093 0.3786 0.3917 0.37994 0.4069 0.4163 0.3751 0.3788 0.3888 0.3749Average 0.3973 0.4083 0.3909 0.3853 0.3874 0.3748

[0189] Table 5B lists the specificity of the assay at high GSH concentration (-1.4 mmol / L) in the presence of different concentrations of intralipid. The GSH measurement for all the samples was inDocket No. J5363-26802the range of 1.35-1.42, regardless the presence or concentration of intralipid. No interference was observed.

[0190] Table 5B. Analytical Interferences - Lipemia, GSH High ConcentrationIntralipid0 31 62 125 250 500 1000 (mg / dL)1 1.379 1.469 1.344 1.403 1.396 1.379 1.3422 1.388 1.359 1.367 1.417 1.374 1.389 1.3743 1.388 1.445 1.357 1.380 1.377 1.367 1.329Average 1.385 1.424 1.356 1.400 1.382 1.378 1.348

[0191] Jaundice, also known as icterus, is a condition characterized by the yellowing of the skin, mucous membranes, and whites of the eyes due to elevated levels of bilirubin in the blood.Accordingly, the specificity of the assay was also evaluated against bilirubin. Bilirubin was added into whole blood samples at concentrations of 0, 2.5, 5, 10, 20, and 40 mg / dL, where the whole blood samples contained low (~0.4 mmol / L) or high (-1.4 mmol / L) concentration of GSH.

[0192] Table 5C lists the specificity of the assay at low GSH concentration (-0.4 mmol / L) in the presence of different concentrations of bilirubin. The GSH measurement for all the samples was in the range of 0.37-0.41, regardless the presence or concentration of bilirubin. No interference was observed.

[0193] Table 5C. Analytical Interferences - Icterus, GSH Low ConcentrationBilrubin (mg / dL) 0 2.5 5 10 20 401 0.3982 0.4055 0.3829 0.3877 0.3871 0.36652 0.3839 0.4005 0.3961 0.3961 0.3819 0.37773 0.4000 0.4109 0.4093 0.3786 0.3917 0.37994 0.4069 0.4163 0.3751 0.3788 0.3888 0.3749Average 0.3973 0.4083 0.3909 0.3853 0.3874 0.3748

[0194] Table 5D lists the specificity of the assay at high GSH concentration (-1.4 mmol / L) in the presence of different concentrations of bilirubin. The GSH measurement for all the samples was in the range of 1.24-1.37, where interference was observed in the presence of high concentration of bilirubin. Bilirubin concentrations higher than 10 mg / dL may interfere with the GSH measurement.

[0195] Table 5D. Analytical Interferences - Icterus, GSH High ConcentrationBilrubin (mg / dL) 0 2.5 5 10 20 401 1.399 1.387 1.339 1.313 1.295 1.2622 1.388 1.385 1.355 1.331 1.269 1.2263 1.324 1.345 1.313 1.299 1.267 1.2634 1.379 1.356 1.367 1.323 1.306 1.225Average 1.372 1.368 1.344 1.316 1.284 1.244Docket No. J5363-26802

[0196] Hemolysis is the breakdown or destruction of red blood cells, leading to the release of hemoglobin into the blood plasma. Accordingly, the specificity of the assay was evaluated against hemoglobin. In particular, hemoglobin was added into whole blood samples at concentrations of 0, 75, 150, 375, 750, and 1500 mg / dL, where the whole blood samples contained low (~0.4 mmol / L) or high (-1.4 mmol / L) concentration of GSH.

[0197] Table 5E lists the specificity of the assay at low GSH concentration (-0.4 mmol / L) in the presence of different concentrations of hemoglobin. At a low concentration of GSH, no level of hemolysis was acceptable.

[0198] At a high level of GSH, concentrations of up to 750 mg / dL hemoglobin were acceptable. It should be noted that as hemoglobin breaks down, iron is released and will alter the oxidative environment of the blood. Therefore, any amount of hemolysis may interfere with the measurement of GSH.

[0199] Table 5E. Analytical Interferences - Hemolysis, GSH Low Concentration Hemoglobin0 75 150 375 750 1500(mg / dL)1 0.3486 0.3729 0.3744 0.3912 0.4217 0.46962 0.3467 0.3689 0.3941 0.3960 0.4370 0.45943 0.3253 0.3709 0.3867 0.3885 0.4137 0.45944 0.3463 0.3689 0.3888 0.3966 0.4219 0.4768Average 0.3417 0.3704 0.3860 0.3931 0.4236 0.4663

[0200] Table 5F. Analytical Interferences - Hemolysis, GSH High Concentration Hemoglobin0 75 150 375 750 1500(mg / dL)1 1.305 1.361 1.356 1.377 1.419 1.4262 1.342 1.332 1.371 1.391 1.389 1.4313 1.327 1.383 1.365 1.378 1.322 1.4284 1.279 1.344 1.378 1.360 1.384 1.419Average 1.313 1.355 1.367 1.376 1.379 1.426Example 5. Carryover

[0201] Carryover effect of the assay was evaluated to determine whether the persistence of GSH from previous samples may interfere with the accurate quantification of subsequent samples. A sample with low GSH concentration (~ 0.1 mmol / L) was run twice, and then thrice after a sample with high GSH concentration (- 9.5 - 10 mmol / L). The test was run in triplicate. Acceptance criteria was that carryover from high concentration samples to low concentration samples should not exceed TEa / 4 for each reported parameter.

[0202] FIG. 7 depicts carryover effect for quantitative measurement of GSH in accordance with various embodiments of the present disclosure. Table 6 also lists carryover effect of GSHDocket No. J5363-26802measurement. Samples with low concentration of GSH was run first (see, cups 1 and 2), followed by samples with high GSH concentration (see, cups 3 and 4). When the low concentration sample was run subsequently, the measurement remained the same (see, cups 5-7). Thus, the assay showed minimum carryover effect. The carryover did not exceed TEa / 4 for any of the measured parameters.

[0203] Table 6. Carryover EffectTEa 25% or 0.10 mmol / LCup # Type Run #1 Run #2 Run #31 Low 0.103 0.102 0.1042 Low 0.106 0.102 0.1063 High 9.801 10.330 9.4844 High 9.531 10.314 9.4725 Low 0.105 0.103 0.1026 Low 0.105 0.106 0.1087 Low 0.110 0.107 0.105Average Low 0.106 0.105 0.104Average High 9.666 10.322 9.478Carry over in Cup 5 -0.001 -0.002 -0.002Carry over in Cup 6 -0.001 0.002 0.003Pre Carry over in Cup 2 0.000 -0.003 0.001Carry overAverage TEa / 4 9No carryCarry over in Cup 5 -0.002 0.025 overNo carryCarry over in Cup 6 0.001 0.025 overNo carryPre -Carry over in Cup 2 -0.001 0.025 over

[0204] Other embodiments

[0205] Al. A method for determining presence or an amount of glutathione by mass spectrometry, the method comprising: subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; purifying the derivatized glutathione from the test sample using liquid chromatography; subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry; determining an amount of the one or more ions by mass spectrometry; and using the amount of the one or more ions to determine the amount of glutathione in the test sample.

[0206] A2. The method of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the test sample prior to the purification.

[0207] A3. The method of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the test sample.Docket No. J5363-26802

[0208] A4. The method of any one of the previous and / or subsequent embodiments, wherein the test sample is subjected to acidic conditions.

[0209] A5. The method of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with acidic conditions comprises contacting the test sample with formic acid.

[0210] A6. The method of any one of the previous and / or subsequent embodiments, wherein the test sample is subject to basic conditions.

[0211] A7. The method of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma.

[0212] A8. The method of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma and ethanol.

[0213] A9. The method of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0214] A 10. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0215] All. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0216] A 12. The method of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0217] A13. The method of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0218] A 14. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0219] A15. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0220] A 16. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0221] A 17. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0222] Al 8. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.Docket No. J5363-26802

[0223] A 19. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0224] A20. The method of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0225] A21. The method of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0226] A22. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of433.2 ± 0.5.

[0227] A23. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0228] A24. The method of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the test sample.

[0229] A25. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0230] A26. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0231] A27. The method of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0232] A28. The method of any one of the previous and / or subsequent embodiments, wherein the test sample comprises a biological sample.

[0233] A29. The method of any one of the previous and / or subsequent embodiments, wherein biological sample comprises a bodily fluid.

[0234] A30. The method of any one of the previous and / or subsequent embodiments, wherein the test sample comprises whole blood.

[0235] BL A method for determining presence or an amount of glutathione by mass spectrometry, the method comprising: subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; adding one or more internal standards into the test sample; purifying the derivatized glutathione and the one or more internal standards from the test sample using liquid chromatography; subjecting the derivatized glutathione and the one or moreDocket No. J5363-26802internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry; determining an amount of the one or more glutathione ions by mass spectrometry; and using the amount of the one or more glutathione ions to determine an amount of glutathione in the test sample.

[0236] B2. The method of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the test sample prior to the purification.

[0237] B3. The method of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the test sample.

[0238] B4. The method of any one of the previous and / or subsequent embodiments, wherein the test sample is subjected to acidic conditions.

[0239] B5. The method of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with acidic conditions comprises contacting the test sample with formic acid.

[0240] B6. The method of any one of the previous and / or subsequent embodiments, wherein the test sample is subject to basic conditions.

[0241] B7. The method of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma.

[0242] B8. The method of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma and ethanol.

[0243] B9. The method of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), and [3-mercaptoethanol (BME).

[0244] B10. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0245] Bll. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, N-ethyhnaleimide .

[0246] B12. The method of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0247] B13. The method of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0248] B14. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.Docket No. J5363-26802

[0249] B15. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0250] Bl 6. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0251] Bl 7. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0252] Bl 8. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0253] Bl 9. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0254] B20. The method of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0255] B21. The method of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0256] B22. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of433.2 ± 0.5.

[0257] B23. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0258] B24. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0259] B25. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0260] B26. The method of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0261] B27. The method of any one of the previous and / or subsequent embodiments, wherein the test sample comprises a biological sample.

[0262] B28. The method of any one of the previous and / or subsequent embodiments, wherein the biological sample comprises a bodily fluid.Docket No. J5363-26802

[0263] B29. The method of any one of the previous and / or subsequent embodiments, wherein the test sample comprises whole blood.

[0264] Cl. A method for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay, the method comprising: obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, wherein the patient sample contains glutathione; subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; purifying the derivatized glutathione from the patient sample using liquid chromatography; subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry; determining an amount of the one or more ions by mass spectrometry; using the amount of the one or more ions to determine the amount of glutathione in the patient sample; and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0265] C2. The method of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the patient sample prior to the purification.

[0266] C3. The method of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the patient sample.

[0267] C4. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample is subjected to acidic conditions.

[0268] C5. The method of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to acidic conditions comprises subjecting the patient sample to formic acid.

[0269] C6. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample is subject to basic conditions.

[0270] C7. The method of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma.

[0271] C8. The method of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma and ethanol.

[0272] C9. The method of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0273] CIO. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.Docket No. J5363-26802

[0274] Cl 1. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0275] C12. The method of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0276] C13. The method of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0277] C14. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0278] C15. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0279] Cl 6. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0280] Cl 7. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0281] Cl 8. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0282] Cl 9. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0283] C20. The method of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0284] C21. The method of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0285] C22. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of433.2 ± 0.5.

[0286] C23. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0287] C24. The method of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the patient sample.Docket No. J5363-26802

[0288] C25. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0289] C26. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0290] C27. The method of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0291] C28. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises a bodily fluid.

[0292] C30. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises whole blood.

[0293] C31. The method of any one of the previous and / or subsequent embodiments, wherein the reference interval is 373-838 pmmol / L.

[0294] C32. The method of any one of the previous and / or subsequent embodiments, wherein exceeding the reference interval comprises greater than an upper limit of the reference interval and / or smaller than a lower limit of the reference interval.

[0295] DI. A method for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay, the method comprising: obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, wherein the patient sample contains glutathione; subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; adding one or more internal standards into the patient sample; purifying the derivatized glutathione and the one or more internal standards from the patient sample using liquid chromatography; subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry; determining an amount of the one or more glutathione ions by mass spectrometry; using the amount of the one or more glutathione ions to determine an amount of glutathione in the patient sample, and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0296] D2. The method of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the patient sample prior to the purification.

[0297] D3. The method of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the patient sample.

[0298] D4. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample is subjected to acidic conditions.Docket No. J5363-26802

[0299] D5. The method of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to acidic conditions comprises subjecting the patient sample to formic acid.

[0300] D6. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample is subject to basic conditions.

[0301] D7. The method of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma.

[0302] D8. The method of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma and ethanol.

[0303] D9. The method of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0304] D10. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0305] Dll. The method of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0306] D12. The method of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0307] D13. The method of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0308] D14. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0309] D15. The method of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0310] DI 6. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0311] DI 7. The method of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0312] DI 8. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0313] DI 9. The method of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.Docket No. J5363-26802

[0314] D20. The method of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0315] D21. The method of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0316] D22. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of433.2 ± 0.5.

[0317] D23. The method of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0318] D24. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0319] D25. The method of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0320] D26. The method of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0321] D28. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises a bodily fluid.

[0322] D29. The method of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises whole blood.

[0323] D30. The method of any one of the previous and / or subsequent embodiments, wherein the reference interval is 373-838 pmmol / L.

[0324] D31. The method of any one of the previous and / or subsequent embodiments, wherein exceeding the reference interval comprises greater than an upper limit of the reference interval and / or smaller than a lower limit of the of the reference interval.

[0325] El . A system for determining presence or an amount of glutathione in a test sample using mass spectrometry, the system comprising: a reaction station for derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione; a purification station for purifying the derivatized glutathione from the test sample by liquid chromatography; and a mass spectrometry station for ionizing the derivatized glutathione to generateDocket No. J5363-26802one or more ions, and determine an amount of the one or more ions, wherein the amount of the one or more ions is related to presence or an amount of glutathione in the test sample.

[0326] E2. The system of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the test sample prior to the purification.

[0327] E3. The system of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the test sample.

[0328] E4. The system of any one of the previous and / or subsequent embodiments, wherein the test sample is subjected to acidic conditions.

[0329] E5. The system of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with acidic conditions comprises contacting the test sample with formic acid.

[0330] E6. The system of any one of the previous and / or subsequent embodiments, wherein the test sample is subject to basic conditions.

[0331] E7. The system of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma.

[0332] E8. The system of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma and ethanol.

[0333] E9. The system of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0334] E10. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0335] Ell. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0336] E12. The system of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0337] E13. The system of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0338] E14. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0339] E15. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).Docket No. J5363-26802

[0340] El 6. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0341] El 7. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0342] El 8. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0343] El 9. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0344] E20. The system of any one of the previous and / or subsequent embodiments, the system has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0345] E21. The system of any one of the previous and / or subsequent embodiments, the system has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0346] E22. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0347] E23. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0348] E24. The system of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the test sample.

[0349] E25. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0350] E26. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0351] E27. The system of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0352] E28. The system of any one of the previous and / or subsequent embodiments, wherein the test sample comprises a biological sample.

[0353] E29. The system of any one of the previous and / or subsequent embodiments, wherein biological sample comprises a bodily fluid.Docket No. J5363-26802

[0354] E30. The system of any one of the previous and / or subsequent embodiments, wherein the test sample comprises whole blood.

[0355] E31. The system of any one of the previous and / or subsequent embodiments, wherein the system is an on-line system.

[0356] Fl . A system for determining presence or an amount of glutathione in a test sample using mass spectrometry, the system comprising: a reaction station for derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, and for adding one or more internal standards into the test sample; a purification station for purifying the derivatized glutathione and the one or more internal standards from the test sample by liquid chromatography; and a mass spectrometry station for ionizing the derivatized glutathione and the one or more internal standards to generate one or more glutathione ions and internal standard ions, and for determining an amount of the one or more glutathione ions, wherein the amount of the one or more glutathione ions is related to presence or an amount of glutathione in the test sample.

[0357] F2. The system of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the test sample prior to the purification.

[0358] F3. The system of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the test sample.

[0359] F4. The system of any one of the previous and / or subsequent embodiments, wherein the test sample is subjected to acidic conditions.

[0360] F5. The system of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with acidic conditions comprises contacting the test sample with formic acid.

[0361] F6. The system of any one of the previous and / or subsequent embodiments, wherein the test sample is subject to basic conditions.

[0362] F7. The system of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma.

[0363] F8. The system of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma and ethanol.

[0364] F9. The system of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or P-mercaptoethanol (BME).

[0365] F10. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.Docket No. J5363-26802

[0366] Fl 1. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0367] F12. The system of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0368] F13. The system of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0369] F14. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0370] F15. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0371] Fl 6. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0372] Fl 7. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0373] Fl 8. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0374] Fl 9. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0375] F20. The system of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0376] F21. The system of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0377] F22. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0378] F23. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0379] F24. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.Docket No. J5363-26802

[0380] F25. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0381] F26. The system of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0382] F27. The system of any one of the previous and / or subsequent embodiments, wherein the test sample comprises a biological sample.

[0383] F28. The system of any one of the previous and / or subsequent embodiments, wherein biological sample comprises a bodily fluid.

[0384] F29. The system of any one of the previous and / or subsequent embodiments, wherein the test sample comprises whole blood.

[0385] Gl. A system for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay, the system comprising: a reaction station for receiving a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, and for derivatizing glutathione in the patient sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione; a purification station for purifying the derivatized glutathione from the patient sample by liquid chromatography; a mass spectrometry station for ionizing the derivatized glutathione to generate one or more ions, and determine an amount of the one or more ions, wherein the amount of the one or more ions is related to presence or an amount of glutathione in the patient sample; and a computer for diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0386] G2. The system of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the patient sample prior to the purification.

[0387] G3. The system of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the patient sample.

[0388] G4. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample is subjected to acidic conditions.

[0389] G5. The system of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to acidic conditions comprises subjecting the patient sample to formic acid.

[0390] G6. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample is subject to basic conditions.

[0391] G7. The system of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma.Docket No. J5363-26802

[0392] G8. The system of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma and ethanol.

[0393] G9. The system of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0394] G10. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0395] Gil. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0396] G12. The system of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0397] G13. The system of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0398] G14. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0399] G15. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization.

[0400] G16. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0401] G17. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0402] G18. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0403] G19. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0404] G20. The system of any one of the previous and / or subsequent embodiments, the system has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0405] G21. The system of any one of the previous and / or subsequent embodiments, the system has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.Docket No. J5363-26802

[0406] G22. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0407] G23. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0408] G24. The system of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the test sample.

[0409] G25. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0410] G26. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0411] G27. The system of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0412] G28. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises a bodily fluid.

[0413] G29. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises whole blood.

[0414] G30. The system of any one of the previous and / or subsequent embodiments, wherein the system is an on-line system.

[0415] G31. The system of any one of the previous and / or subsequent embodiments, wherein the reference interval is 373-838 pmmol / L.

[0416] G32. The system of any one of the previous and / or subsequent embodiments, wherein exceeding the reference interval comprises greater than an upper limit of the reference interval and / or smaller than a lower limit of the reference interval.

[0417] Hl. A system for diagnosing patients with glutathione deficiency and / or dysfunction with a mass spectrometric assay, the system comprising: a reaction station for receiving a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, derivatizing glutathione in the patient sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione, and adding one or more internal standards into the patient sample; a purification station for purifying the derivatized glutathione and the one or more internal standards from the patient sample by liquid chromatography; a mass spectrometry station for ionizing the derivatized glutathione and the one or more internal standards to generate one or more glutathione ions and internal standard ions, andDocket No. J5363-26802determine an amount of the one or more glutathione ions, wherein the amount of the one or more glutathione ions is related to presence or an amount of glutathione in the patient sample; and a computer for diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0418] H2. The system of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the patient sample prior to the purification.

[0419] H3. The system of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the patient sample.

[0420] H4. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample is subjected to acidic conditions.

[0421] H5. The system of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to acidic conditions comprises subjecting the patient sample to formic acid.

[0422] H6. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample is subject to basic conditions.

[0423] H7. The system of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma.

[0424] H8. The system of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma and ethanol.

[0425] H9. The system of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0426] H10. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0427] Hll. The system of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethylmaleimide.

[0428] H12. The system of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0429] Hl 3. The system of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0430] H14. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.Docket No. J5363-26802

[0431] Hl 5. The system of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization.

[0432] Hl 6. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0433] Hl 7. The system of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0434] Hl 8. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0435] Hl 9. The system of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0436] H20. The system of any one of the previous and / or subsequent embodiments, the system has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0437] H21. The system of any one of the previous and / or subsequent embodiments, the system has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0438] H22. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0439] H23. The system of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0440] H24. The system of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the test sample.

[0441] H25. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0442] H26. The system of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0443] H27. The system of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0444] H28. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises a bodily fluid.Docket No. J5363-26802

[0445] H29. The system of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises whole blood.

[0446] H30. The system of any one of the previous and / or subsequent embodiments, wherein the system is an on-line system.

[0447] H31. The system of any one of the previous and / or subsequent embodiments, wherein the reference interval is 373-838 pmmol / L.

[0448] H32. The system of any one of the previous and / or subsequent embodiments, wherein exceeding the reference interval comprises greater than an upper limit of the reference interval and / or smaller than a lower limit of the reference interval.

[0449] II. Non-transitory computer readable storage medium storing instructions that, when executed by at least one processor, cause a computing system to perform actions comprising: subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; purifying the derivatized glutathione from the test sample using liquid chromatography; subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry; determining an amount of the one or more ions by mass spectrometry; and using the amount of the one or more ions to determine the amount of glutathione in the test sample.

[0450] 12. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the test sample prior to the purification.

[0451] 13. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the test sample.

[0452] 14. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample is subjected to acidic conditions.

[0453] 15. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with acidic conditions comprises contacting the test sample with formic acid.

[0454] 16. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample is subject to basic conditions.

[0455] 17. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma.

[0456] 18. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma and ethanol.Docket No. J5363-26802

[0457] 19. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0458] 110. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0459] Ill. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methyhnaleimide, N-(1 -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethyhnaleimide.

[0460] 112. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0461] 113. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0462] 114. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0463] 115. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0464] 116. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0465] 117. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0466] 118. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0467] 119. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0468] 120. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0469] 121. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.Docket No. J5363-26802

[0470] 122. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0471] 123. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0472] 124. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the test sample.

[0473] 125. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0474] 126. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0475] 127. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0476] 128. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample comprises a biological sample.

[0477] 129. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein biological sample comprises a bodily fluid.

[0478] 130. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample comprises whole blood.

[0479] JI . Non-transitory computer readable storage medium storing instructions that, when executed by at least one processor, cause a computing system to perform actions comprising: subjecting a test sample containing glutathione to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; adding one or more internal standards into the test sample; purifying the derivatized glutathione and the one or more internal standards from the test sample using liquid chromatography; subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry; determining an amount of the one or more glutathione ions by mass spectrometry; and using the amount of the one or more glutathione ions to determine an amount of glutathione in the test sample.Docket No. J5363-26802

[0480] J2. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the test sample prior to the purification.

[0481] J3. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the test sample.

[0482] J4. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample is subjected to acidic conditions.

[0483] J5. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with acidic conditions comprises contacting the test sample with formic acid.

[0484] J6. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample is subject to basic conditions.

[0485] J7. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma.

[0486] J8. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein contacting the test sample with basic conditions comprises contacting the test sample with trizma and ethanol.

[0487] J9. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyljphosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0488] JI 0. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0489] JI 1. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(1 -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethyhnaleimide.

[0490] J12. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0491] JI 3. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0492] J14. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.Docket No. J5363-26802

[0493] J 15. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0494] JI 6. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0495] JI 7. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0496] JI 8. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0497] JI 9. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0498] J20. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0499] J21. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0500] J22. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0501] J23. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0502] J24. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0503] J25. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0504] J26. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0505] J27. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample comprises a biological sample.DocketNo. J5363-26802

[0506] J28. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the biological sample comprises a bodily fluid.

[0507] J29. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the test sample comprises whole blood.

[0508] KI. Non-transitory computer readable storage medium storing instructions that, when executed by at least one processor, cause a computing system to perform actions comprising: obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, wherein the patient sample contains glutathione; subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; purifying the derivatized glutathione from the patient sample using liquid chromatography; subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more ions detectable by mass spectrometry; determining an amount of the one or more ions by mass spectrometry; using the amount of the one or more ions to determine the amount of glutathione in the patient sample; and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0509] K2. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the patient sample prior to the purification.

[0510] K3. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the patient sample.

[0511] K4. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample is subjected to acidic conditions.

[0512] K5. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to acidic conditions comprises subjecting the patient sample to formic acid.

[0513] K6. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample is subject to basic conditions.

[0514] K7. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma.

[0515] K8. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma and ethanol.

[0516] K9. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-Docket No. J5363-26802carboxyethyl)phosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0517] K10. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0518] KI 1. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methyhnaleimide, N-(1 -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethyhnaleimide.

[0519] K12. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).

[0520] KI 3. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0521] K14. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0522] KI 5. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0523] KI 6. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0524] KI 7. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0525] KI 8. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0526] KI 9. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0527] K20. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0528] K21. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.Docket No. J5363-26802

[0529] K22. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0530] K23. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0531] K24. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising adding one or more internal standards into the patient sample.

[0532] K25. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0533] K26. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0534] K27. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generate one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0535] K28. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises a bodily fluid.

[0536] K29. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises whole blood.

[0537] K30. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the reference interval is 373-838 pmmol / L.

[0538] K31. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein exceeding the reference interval comprises greater than an upper limit of the reference interval and / or smaller than a lower limit of the reference interval.

[0539] LI . Non-transitory computer readable storage medium storing instructions that, when executed by at least one processor, cause a computing system to perform actions comprising: obtaining a patient sample from a patient suspected of glutathione deficiency and / or dysfunction, wherein the patient sample contains glutathione; subjecting the patient sample to a reducing reagent and a derivatizing reagent to generate derivatized glutathione; adding one or more internal standards into the patient sample; purifying the derivatized glutathione and the one or more internal standards from the patient sample using liquid chromatography; subjecting the derivatized glutathione and the one or more internal standards to an ionization source under conditions suitable to generate one or more glutathione ions and internal standard ions detectable by mass spectrometry; determining anDocket No. J5363-26802amount of the one or more glutathione ions by mass spectrometry; using the amount of the one or more glutathione ions to determine an amount of glutathione in the patient sample, and diagnosing the patient with glutathione deficiency and / or dysfunction when the amount of glutathione in the patient sample exceeds a reference interval.

[0540] L2. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising extracting glutathione from the patient sample prior to the purification.

[0541] L3. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the extracting comprises protein precipitation from the patient sample.

[0542] L4. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample is subjected to acidic conditions.

[0543] L5. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to acidic conditions comprises subjecting the patient sample to formic acid.

[0544] L6. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample is subject to basic conditions.

[0545] L7. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma.

[0546] L8. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein subjecting the patient sample to basic conditions comprises subjecting the patient sample to trizma and ethanol.

[0547] L9. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the reducing reagent is selected from tris(2-carboxyethyljphosphine (TCEP), tributylphosphine, dithiothreitol (DTT), dithioerythritol (DTE), or [3-mercaptoethanol (BME).

[0548] L10. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent comprises maleimide.

[0549] Lil. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the derivatizing reagent is selected from N-methylmaleimide, N-(1 -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N-ethyhnaleimide.

[0550] L12. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the liquid chromatography comprises one or more of high performance liquid chromatography (HPLC), high turbulence liquid chromatography (HTLC), high-resolution liquid chromatography, and ultra-high performance liquid chromatography (UHPLC).Docket No. J5363-26802

[0551] L13. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the purification comprises liquid-liquid extraction and / or solid phase extraction.

[0552] L14. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises electrospray ionization.

[0553] L15. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization comprises atmospheric pressure chemical ionization (APCI).

[0554] LI 6. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in positive ion mode.

[0555] LI 7. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the ionization is in negative ion mode.

[0556] LI 8. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry is performed in multiple reaction monitoring mode.

[0557] LI 9. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the mass spectrometry comprises tandem mass spectrometry.

[0558] L20. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0559] L21. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, the method has a clinical portable range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

[0560] L22. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione precursor ions with a mass-to-charge (m / z) ratio of 433.2 ± 0.5.

[0561] L23. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more ions comprises one or more glutathione fragment ions with a mass-to-charge (m / z) ratio selected from 304.1 ± 0.5 or 287.1 ± 0.5.

[0562] L24. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are isotopically labeled.

[0563] L25. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the one or more internal standards are selected from N-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0564] L26. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, further comprising ionizing the one or more internal standards to generateDocket No. J5363-26802one or more internal standard ions with a mass-to-charge (m / z) ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5, and measuring an amount of the one or more internal standard ions.

[0565] L27. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises a bodily fluid.

[0566] L28. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the patient sample comprises whole blood.

[0567] L29. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein the reference interval is 373-838 pmmol / L.

[0568] L30. The non-transitory computer readable storage medium of any one of the previous and / or subsequent embodiments, wherein exceeding the reference interval comprises greater than an upper limit of the reference interval and / or smaller than a lower limit of the of the reference interval.

[0569] Ml. A kit for a quantitative assay of measuring glutathione in a sample using mass spectrometry, the kit comprising an internal standard in an amount sufficient for performing at least one assay for measuring glutathione.

[0570] M2. The kit of any one of the previous and / or subsequent embodiments, wherein the internal standard for measuring glutathione is isotopically labeled.

[0571] M3. The kit of any one of the previous and / or subsequent embodiments, wherein the internal standard is labeled with one or more isotopes selected from deuterium (2H),13C,15N or18O.

[0572] M4. The kit of any one of the previous and / or subsequent embodiments, wherein the isotopically labeled internal standard comprises an isotopically labeled glutathione.

[0573] M5. The kit of any one of the previous and / or subsequent embodiments, wherein the isotopically labeled internal standard comprises an isotopically labeled glutathione disulfide.

[0574] M6. The kit of any one of the previous and / or subsequent embodiments, wherein the isotopically labeled comprises one or more ofN-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.

[0575] M7. The kit of any one of the previous and / or subsequent embodiments, wherein the isotopically labeled comprises one or more of GSH (glycine-13C-15N), GSH (glycine-13C2-15N), or GSH (cysteinyl-13Cs).

[0576] M8. The kit of any one of the previous and / or subsequent embodiments, wherein the isotopically labeled comprises one or more of GSSG (glycine-13C-15N), GSSG (glycine-13C2-15N), or GSSG (cysteinyl-13C3).

[0577] The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicant reserves the right to physically incorporate intoDocket No. J5363-26802this application any and all materials and information from any such articles, patents, patent applications, or other physical and electronic documents.

[0578] The methods illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. For example, the terms “comprising”, “including,” containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the invention embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[0579] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the methods. This includes the generic description of the methods with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[0580] Other embodiments are within the following claims. In addition, where features or aspects of the methods are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

Claims

Docket No. J5363-26802CLAIMS WHAT IS CLAIMED IS:

1. A method for determining presence or an amount of glutathione by mass spectrometry, the method comprising:contacting a test sample comprising glutathione with a reducing reagent and a derivatizing reagent to generate derivatized glutathione;purifying the derivatized glutathione from the test sample using liquid chromatography; subjecting the derivatized glutathione to an ionization source under conditions suitable to ionize the derivatized glutathione and generate a quantifying fragment ion and a qualifying fragment ion detectable by mass spectrometry;determining an amount of the quantifying fragment ion by mass spectrometry, wherein the amount of the quantifying fragment ion is correlated to the amount of glutathione in the test sample.

2. The method of claim 1, further comprising extracting glutathione from the test sample prior to the purification.

3. The method of claim 2, wherein the extracting comprises protein precipitation from the test sample.

4. The method of claim 1, wherein the reducing reagent comprises one or more of tris(2- carboxyethyljphosphine, tributylphosphine, dithiothreitol, dithioerythritol, or P-mercaptoethanol.

5. The method of claim 1, wherein the derivatizing reagent comprises maleimide.

6. The method of claim 1, wherein the derivatizing reagent comprises one or more of N- methyhnaleimide, N-(l -phenylethyl) maleimide, p-N,N'-phenylenebismaleimide, or N- ethylmaleimide.

7. The method of claim 1, wherein the liquid chromatography comprises high performance liquid chromatography (HPLC).

8. The method of claim 1, wherein the ionization comprises electrospray ionization.

9. The method of claim 1, wherein the mass spectrometry comprises tandem mass spectrometry.

10. The method of claim 1, wherein the ionizing further comprises subjecting the derivatized glutathione to the ionization source under conditions suitable to ionize the derivatized glutathione and generate one or more glutathione precursor ions with a m / z ratio of 433.2 ± 0.5.

11. The method of claim 1, wherein the quantifying fragment ion has a m / z ratio of 304.1 ± 0.

5.

12. The method of claim 1, wherein the qualifying fragment ion has a m / z ratio of 287.1 ± 0.5.

13. The method of claim 1, further comprising adding one or more internal standards.

14. The method of claim 13, wherein the one or more internal standards are isotopically labeled.

15. The method of claim 13, wherein the one or more internal standards comprise one or more of N- ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, or13C2-15N-glutathione-NEM-d5.Docket No. J5363-2680216. The method of claim 13, further comprising:ionizing the one or more internal standards to generate one or more internal standard ions with a m / z ratio selected from 441.0 ± 0.5 or 312.0 ± 0.5; andmeasuring an amount of the one or more internal standard ions.

17. The method of claim 1, wherein the method has an analytical measurement range for glutathione across a range between about 0.1 mmol / L and about 10 mmol / L.

18. The method of claim 1, wherein the test sample comprises a biological sample.

19. A system for determining presence or an amount of glutathione in a test sample using mass spectrometry, the system comprising:a reaction station for derivatizing glutathione in a test sample with a reducing reagent and a derivatizing reagent to generate derivatized glutathione;a purification station for purifying the derivatized glutathione from the test sample by liquid chromatography; anda mass spectrometry station for ionizing the derivatized glutathione to generate a quantifying fragment ion and a qualifying fragment ion, and determining an amount of the quantifying fragment ion, wherein the amount of the quantifying fragment ion is related to presence or an amount of glutathione in the test sample.

20. A kit for use in a method of determining the presence or an amount of glutathione by mass spectrometry comprising one or more isotopically labeled analogues of glutathione as internal standards.

21. The kit of claim 20, wherein the one or more internal standards are labeled with one or more deuterium (2H),13C, and / or15N atoms.

22. The kit of claim 21, wherein the one or more internal standards are selected from the group consisting ofN-ethyl-maleimide-d5 (NEM-d5),13C-15N-glutathione-NEM-d5, and13C2-15N- glutathione-NEM-d5.